{"text": "Results of this sensitivity analysis were essentially the same , except that the original significant group differences on medication cost ( with significantly higher medication cost for patients with prior relapse ) became statistically non - significant .", "label": "", "metadata": {}, "score": "36.690475"}
{"text": "The additional efficacy of AZA in comparison with prednisone alone has to be confirmed with randomized , controlled trials .This account is pending registration confirmation .", "label": "", "metadata": {}, "score": "36.86917"}
{"text": "It was hypothesized that patients with prior relapse will incur significantly higher total direct mental health cost in the following year than patients without prior relapse and that in addition to higher inpatient hospitalization cost they will incur significantly higher cost of outpatient services .", "label": "", "metadata": {}, "score": "37.4878"}
{"text": "The excluded patients differed significantly from the included patients on variables shown to be associated with relapse ( e.g. , younger age , prior hospitalizations , poorer adherence , and more severe symptoms ) , suggesting that the overall rate of relapse has likely been underestimated .", "label": "", "metadata": {}, "score": "39.57698"}
{"text": "Accordingly , an additional sensitivity analysis was performed in which 13 such patients were excluded ; results were highly consistent with the original findings ( e.g. , total cost was 2.2 times higher for patients with versus without prior relapse rather than 2.8 times higher ) .", "label": "", "metadata": {}, "score": "39.596107"}
{"text": "A relapse must be confirmed by the Independent Evaluating Physician ( examining neurologist ) .ARR estimates were calculated from a negative binomial regression model adjusted for treatment , pooled center , number of relapses in the previous 2 years prior to enrollment , and Baseline expanded disability status scale ( EDSS ) .", "label": "", "metadata": {}, "score": "39.83046"}
{"text": "Direct cost data were not available for the 6-month pre - study period , but data on relapse , including number of psychiatric hospitalizations and length of stay ( LOS ) were available .", "label": "", "metadata": {}, "score": "40.743362"}
{"text": "The cost differential was primarily driven by a higher number of hospitalizations and by longer hospital stay per admission .The use of these predictors in clinical practice may help improve allocation of resources , such as active case management and adherence interventions , since these programs aim to prevent relapse and hospitalization .", "label": "", "metadata": {}, "score": "40.92379"}
{"text": "As a sensitivity analysis , the a priori propensity score model was modified to include all baseline covariates for which statistically significant group imbalance was found .", "label": "", "metadata": {}, "score": "41.395676"}
{"text": "However , except for results from 1 published study [ 1 ] , information about potential predictors of relapse and its associated treatment costs in the United Stated are scarce .", "label": "", "metadata": {}, "score": "41.52019"}
{"text": "AZA and MTX are effective as maintenance therapy once remission has been achieved .Whilst there is evidence for the use of MMF as an induction agent , the wider applicability of the single study is questionable .", "label": "", "metadata": {}, "score": "41.72413"}
{"text": "In the light of data from Jayne 2003 , it would seem reasonable to suggest that continuous oral CPA should be limited to three months treatment if the patient has achieved a sustained remission with a change to AZA for maintenance therapy .", "label": "", "metadata": {}, "score": "42.291496"}
{"text": "Relapse was associated with higher costs for inpatient services as well as for outpatient services and medication .Patients with prior relapse were younger and had onset of illness at earlier ages , poorer medication adherence , more severe symptoms , a higher prevalence of substance use disorder , and worse functional status .", "label": "", "metadata": {}, "score": "42.47877"}
{"text": "From 12 months both groups received AZA 1.5 mg / kg / d and prednisolone 7.5 mg / d .Relapse by 18 months .Side effects including leucopenia and infections .", "label": "", "metadata": {}, "score": "44.143074"}
{"text": "Although the relapsed patients had significantly higher psychiatric hospitalization and emergency services costs , they also incurred significantly higher costs for medications and various outpatient services , including medication management , day treatment , individual therapy , and ACT / case management .", "label": "", "metadata": {}, "score": "44.277435"}
{"text": "The number of relapses on AZA is similar to CPA with fewer episodes of leukopenia and similar numbers of infections .As well as the data on reduced leukopenia , the reduction in total dose of CPA is presumed to reduce longer term side effects from CPA such as infertility and neoplasia .", "label": "", "metadata": {}, "score": "44.705154"}
{"text": "The use of AZA to reduce exposure to CPA is assessed by Jayne et al [ 39 ] .Patients were treated with standard induction therapy of CPA 2 mg / kg / d and prednisolone 1 mg / kg / d .", "label": "", "metadata": {}, "score": "44.817364"}
{"text": "To determine predictors of relapse during the 1-year study period , a stepwise logistic regression analyses was conducted for ( 1 ) all patients , ( 2 ) patients with prior relapse , and ( 3 ) patients without prior relapse .", "label": "", "metadata": {}, "score": "44.826828"}
{"text": "To validate the accuracy of the prespecified low versus high relapse indicator variable ( I_L / H ) as a predictor of relapse after induction therapy .", "label": "", "metadata": {}, "score": "45.013985"}
{"text": "Primary outcomes were relapse by 18 months and side effects of treatment .The introduction of AZA after remission did not alter the rate of relapse at 18 months compared to the group who remained on CPA ( 1 study ; RR 1.13 , 95 % CI 0.51 - 2.5 ) .", "label": "", "metadata": {}, "score": "45.461884"}
{"text": "Brachytherapy which overcomes these problems was investigated to deliver the boost dose to achieve 85 Gy .PSA nadir which has been identified as the strongest independent predictor of any failure in many studies has been used as the end point for early evaluation of this work .", "label": "", "metadata": {}, "score": "45.527428"}
{"text": "Consistent with prior antipsychotic drug cost research [ 16 , 17 ] , the costs of atypical antipsychotic medications were based on average wholesale prices discounted by 15 % , reflecting the customary discount level in the United States .", "label": "", "metadata": {}, "score": "45.80223"}
{"text": "ARR estimates were calculated from a negative binomial regression model adjusted for treatment , pooled center , number of relapses in the previous 2 years prior to enrollment , and Baseline expanded disability status scale ( EDSS ) .", "label": "", "metadata": {}, "score": "45.87986"}
{"text": "Relapse rate ( 62 vs 44 % , P\u00bc0.05 ) and mortality ( 59 vs 43 % , P\u00bc0.05 ) were significantly higher in patients with methylated ASPP1 .", "label": "", "metadata": {}, "score": "46.063972"}
{"text": "Prior relapse was a robust predictor of subsequent relapse , above and beyond information about patients ' functioning and symptom levels .Conclusions .Despite the historical decline in utilization of psychiatric inpatient services , relapse remains an important predictor of subsequent relapse and treatment costs for persons with schizophrenia .", "label": "", "metadata": {}, "score": "46.336983"}
{"text": "No particular clinical variables were found to predict renal remission or relapses .Over a mean follow - up of 90 months , 13 % of patients had decline of creatinine clearance by 20 % , but none had doubling of serum creatinine .", "label": "", "metadata": {}, "score": "46.35477"}
{"text": "Using a robust and simple clinical marker such as recent relapse may help improve the accuracy of Medicare risk adjustment models .This information may also be applicable to risk adjustments of premiums under Medicare Part D plans because drug expenditures in the previous year generally had been found to be strongly predictive of current - year drug expenditures for individuals [ 23 , 24 ] .", "label": "", "metadata": {}, "score": "46.67001"}
{"text": "These treatments are well established but many questions remain unanswered [ 12 ] .Optimal agent , dose , duration , route and frequency of treatment are uncertain .", "label": "", "metadata": {}, "score": "46.730873"}
{"text": "Baseline predictors of subsequent relapse were also assessed .Results .Of 1,557 participants with eligible data , 310 ( 20 % ) relapsed during the 6 months prior to the 1-year study period .", "label": "", "metadata": {}, "score": "47.03943"}
{"text": "Previous studies have shown an effect in the most severely ill patients .A subgroup analysis in Pusey 1991 showed a benefit for patients requiring dialysis at presentation .", "label": "", "metadata": {}, "score": "47.81747"}
{"text": "Third , the study did not have complete mental health resources information for all patients across the 3-year study , thus curtailing the ability to assess change in costs over time .", "label": "", "metadata": {}, "score": "48.099194"}
{"text": "Using prescription information in patient medical records , the MPR was calculated as the proportion of days with any antipsychotic medication .An MPR value of at least .80 is considered being adherent [ 6 ] .", "label": "", "metadata": {}, "score": "48.386612"}
{"text": "Therapeutic monitoring was assessed by use of serum prostate - specific antigen ( PSA ) measurements .Patients in the CAD and IAD groups were equally stratified for age , biopsy Gleason score , and baseline serum PSA levels .", "label": "", "metadata": {}, "score": "48.42596"}
{"text": "Maintenance treatment with low - dose prednisone and AZA was continued indefinitely for those who achieved remission .Factors predictive of initial renal remission and subsequent relapse were studied by statistical analyses .", "label": "", "metadata": {}, "score": "48.434883"}
{"text": "N Engl J Med 1996 , 335 : 16 - 20 .View Article PubMed .R\u00fcth E , Kemper MJ , Leumann EP , Laube GF , Neuhaus TJ : Children with steroid - sensitive nephrotic syndrome come of age : long - term outcome .", "label": "", "metadata": {}, "score": "48.58438"}
{"text": "The remission rate is also lower than that achieved in similar studies from Europe with only 44 % of patients achieving remission as opposed to over 90 % ( Jayne 2003 ) .", "label": "", "metadata": {}, "score": "48.637756"}
{"text": "And lastly , the results of this study may not be generalizable to patients with schizophrenia whose treatment is covered by private payers because public payers covered almost all US - SCAP participants [ 10 , 27 ] .", "label": "", "metadata": {}, "score": "48.776726"}
{"text": "leading to discontinuation of the study drug .Secondary end points : . any adverse event , . severe adverse event , . relapse , . relapse free survival , .", "label": "", "metadata": {}, "score": "49.075684"}
{"text": "There was no difference in the induction of sustained remission ( 1 study ; risk ratio 0.93 ; 95 % confidence interval 0.77 to 1.11 ) or relapse rate ( 1 study ; risk ratio 0.93 ; 95 % confidence interval 0.56 to 1.56 ) .", "label": "", "metadata": {}, "score": "49.349266"}
{"text": "Initial results suggest that there is no major benefit in terms of efficacy with rituximab compared with cyclophosphamide .Cost savings may be evident in avoidance of adverse events but this requires further study .", "label": "", "metadata": {}, "score": "49.614872"}
{"text": "If the relapse rate is particularly high , MMF may simply turn out to be an expensive prelude to CPA .The population in this trial is significantly different from those in other studies , most obviously in the proportion of patients with MPO - ANCA and microscopic polyangiitis at 87 % .", "label": "", "metadata": {}, "score": "49.65641"}
{"text": "The first year of patients ' participation in the study was often the study year .In addition to comparing patients with and without prior relapse on baseline characteristics and on mental health costs , the impact of prior relapse on subsequent relapse ( within the following year ) was assessed .", "label": "", "metadata": {}, "score": "49.718533"}
{"text": "This analysis strongly suggests that , although pulse treatment with cyclophosphamide is equivalent to continuous treatment for remission induction , it results in a higher rate of relapse subsequently .", "label": "", "metadata": {}, "score": "49.739777"}
{"text": "Hiemstra T , Walsh M , Schmitt W , Jayne D : Randomised controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in anca associated vasculitis ( improve ) [ abstract].", "label": "", "metadata": {}, "score": "49.874588"}
{"text": "Intravenous regimens tend to give a lower total dose and have fewer side effects , but may later give a higher rate of relapse [ 13 ] .", "label": "", "metadata": {}, "score": "49.90918"}
{"text": "Authors ' Conclusions .Implications for practice .Plasma exchange is effective in patients with severe ARF secondary to vasculitis .On current data , the use of pulse CPA results in an increased risk of relapse when compared to continuous use but a reduced total CPA dose .", "label": "", "metadata": {}, "score": "49.971973"}
{"text": "Time to relapse was shorter for the MMF group but this has not yet been reported in detail .Azathioprine vs Methotrexate for maintenance treatment .", "label": "", "metadata": {}, "score": "50.056904"}
{"text": "As the population of patients evolves over time and patients with milder disease are treated , it is highly likely that any cost effectiveness analysis would suggest that a minor benefit potentially conferred by plasma exchange would come at too great a cost when compared with IV methylprednisolone .", "label": "", "metadata": {}, "score": "50.076733"}
{"text": "Panel A. CLU re - expression in melanoma cells in response to Aza ( 0.2 \u00b5M ) as assessed by the oligonucleotide array hybridization .The data represent one of three sequence IDs with similar results .", "label": "", "metadata": {}, "score": "50.088013"}
{"text": "As shown in Additional file 2 , significant differences were observed between these 4 groups on baseline characteristics and cost parameters .Compared to the NR group , patients with prior relapse but without subsequent relapse ( RN ) were younger , less likely to have health insurance , had a higher hospitalization rate in the year prior to study enrollment , and had better physical health functioning .", "label": "", "metadata": {}, "score": "50.296436"}
{"text": "Furthermore , to help assess whether knowledge about previous relapse improves the ability to predict subsequent treatment costs over and above potential associations with patients ' current level of functioning and symptomatology , we have conducted a sensitivity analysis .", "label": "", "metadata": {}, "score": "50.720554"}
{"text": "Among patients with prior relapse ( RN vs. RR groups , Additional file 3B ) , the predictors were more severe schizophrenia symptoms per PANSS and a higher number of psychiatric hospital admissions in the prior year .", "label": "", "metadata": {}, "score": "50.91712"}
{"text": "The biopsies were triggered either by an abnormally high PSA value or by suspicious findings on DRE .Patients with other known or suspected urinary malignancy were excluded from the study .", "label": "", "metadata": {}, "score": "50.990314"}
{"text": "The study is an open - label , multiple - dose , dose - escalation study , which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to a total of approximately 15 relapsed or refractory multiple myeloma patients .", "label": "", "metadata": {}, "score": "51.126358"}
{"text": "In addition , the cost for the RN group was 1.5 times that of the NN group , demonstrating again the economic impact of prior relapse even when no subsequent relapse took place .", "label": "", "metadata": {}, "score": "51.219612"}
{"text": "Two patients withdrew from the protocol because of idiosyncratic reactions to AZA .At 12 months , 24 ( 67 % ) patients achieved complete remission ( CR ) , 8 ( 22 % ) achieved partial remission ( PR ) , and 4 ( 11 % ) were treatment resistant .", "label": "", "metadata": {}, "score": "51.296753"}
{"text": "WGET 2005 .Patients with BVAS / WG score of 3 or more .Stratified to severe ( life - threatening manifestations including RPGN , alveolar haemorrhage or neuropathy ) or limited ( skin , joints , sinus or mild renal abnormalities ) .", "label": "", "metadata": {}, "score": "51.391785"}
{"text": "Tapered to 0 mg at 6 months if no relapse .Sustained remission .BVAS / WG score 0 for at least 6 months .Metzler 2007 .", "label": "", "metadata": {}, "score": "51.522434"}
{"text": "Primary outcomes were death , remission and relapse rate .The reduction in the number of relapses in patients treated with co - trimoxazole was a significant result on the basis of life - table analysis , giving a reported RR of relapse of 0.40 ( 95 % CI 0.17 to 0.98 ) .", "label": "", "metadata": {}, "score": "51.569866"}
{"text": "Mycophenolate mofetil may be equivalent to cyclophosphamide as an induction agent but resulted in a higher relapse rate when tested against Azathioprine in remission maintenance .", "label": "", "metadata": {}, "score": "51.649982"}
{"text": "View Article PubMed .Valenstein M , Copeland LA , Blow FC , McCarthy JF , Zeber JE , Gillon L , Bingham CR , Stavenger T : Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission .", "label": "", "metadata": {}, "score": "51.695694"}
{"text": "MMF was found to be equivalent to CPA in this limited population for remission at 6 months ( 1 study ; risk ratio 1.65 ; 95 % confidence interval 0.94 to 2.90 ) .", "label": "", "metadata": {}, "score": "51.89194"}
{"text": "View Article PubMed .Nowack R , Birck R , van der Woude FJ : Mycophenolate mofetil for systemic vasculitis and IgA nephropathy .Lancet 1997 , 349 : 774 .", "label": "", "metadata": {}, "score": "52.004974"}
{"text": "Future research is needed to evaluate the longer - term effects on patient outcomes and health care costs of targeting different interventions to patients at high risk of relapse .", "label": "", "metadata": {}, "score": "52.0196"}
{"text": "A structured interview was used to identify sociodemographic characteristics .Level of symptom severity was assessed annually with the Positive and Negative Syndrome Scale ( PANSS ) [ 13 ] and the Montgomery - \u00c5sberg Depression Rating Scale ( MADRS ) [ 14 ] .", "label": "", "metadata": {}, "score": "52.06485"}
{"text": "Schizophr Bull 2008 , 34 ( 1 ) : 173 - 180 .View Article PubMed .Sun SX , Liu GG , Christensen DB , Fu AZ : Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States .", "label": "", "metadata": {}, "score": "52.208214"}
{"text": "Supplemental data provide the growth curves ( ) and the population doubling time ( ) of all cell strains .Panel B. Aza IC50 response .", "label": "", "metadata": {}, "score": "52.264008"}
{"text": "Many commentators felt this to be an inadequate dose , potentially causing the higher relapse rate and reflecting poorly the potential of methotrexate in this area .", "label": "", "metadata": {}, "score": "52.36798"}
{"text": "There was no detected difference in efficacy between immunoadsorption and plasma exchange , as assessed by mortality , the need for dialysis and SCr .Lymphocytapheresis is compared to 3 days of iv methylprednisolone as adjunctive therapy by Furuta et al [ 37 ] .", "label": "", "metadata": {}, "score": "52.386574"}
{"text": "Abstract .BACKGROUND : .The aim of this study was to report the outcome of pure membranous lupus nephropathy treated with prednisone and azathioprine ( AZA ) .", "label": "", "metadata": {}, "score": "52.41934"}
{"text": "The UK cohort seemed to have more severe disease than the Japanese cohort , with more severe onset attacks , a higher relapse frequency and greater disability at follow - up , despite earlier immunosuppression .", "label": "", "metadata": {}, "score": "52.425087"}
{"text": "Mental and physical levels of functioning were assessed with the 12-Item Short Form Health Survey ( SF-12 ) [ 15 ] .Patient - reported medication adherence was assessed with SCAP - HQ on a 5-point scale .", "label": "", "metadata": {}, "score": "52.4253"}
{"text": "Values are average of duplicate wells .Bars indicate double standard errors that ranged between 5 - 10 % of total counts .Similar results were obtained with 1 nM Bortezomib in combination with Aza .", "label": "", "metadata": {}, "score": "52.426903"}
{"text": "Comparisons between groups by prior and subsequent relapse status .These findings indicate that among the non - relapsed in the 1-year follow - up period , 87.6 % ( 1078 of 1231 ) were correctly identified as non - relapsed based on their prior 6-month status ( relapsed or not ) .", "label": "", "metadata": {}, "score": "52.436905"}
{"text": "Initial statistical group comparisons assessed patients who relapsed during the prior 6 months compared with patients who did not ( RR and RN versus NR and NN ) .", "label": "", "metadata": {}, "score": "52.46141"}
{"text": "Prednisolone allowed at a dose of 10 mg / d or less .In the absence of disease activity , the dose was tapered by 2.5 mg / month to 5 mg , then by 1 mg / month .", "label": "", "metadata": {}, "score": "52.4907"}
{"text": "Gilmer TP , Dolder CR , Lacro JP , Folsom DP , Lindamer L , Garcia P , Jeste DV : Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia .", "label": "", "metadata": {}, "score": "52.81649"}
{"text": "Side effects appeared similar on both agents ( risk ratio 0.65 ; 95 % confidence interval 0.20 to 2.14 ) .Intravenous immunoglobulin for treatment of persistent disease .", "label": "", "metadata": {}, "score": "52.83017"}
{"text": "Relapses detected in the study were mainly respiratory in nature but 11/23 patients with a relapse also had progressive glomerulonephritis .Etanercept use .The stated aim of the single study into the use of etanercept in systemic vasculitis was to demonstrate that the relapse rate would be reduced .", "label": "", "metadata": {}, "score": "52.88633"}
{"text": "However , the confidence intervals for these are wide and clinical significance uncertain .No further data has been published to support this study .Maintenance Studies .", "label": "", "metadata": {}, "score": "52.960026"}
{"text": "Mean follow - up was 30.8 months .Median cycle length and percentage of time off therapy were 9.0 months and 59.5 , respectively .Our data suggest that IAD treatment may maintain the androgen - dependent state of advanced human prostate cancer , as assessed by PSA measurements , at least as long as CAD treatment .", "label": "", "metadata": {}, "score": "53.043297"}
{"text": "Discussion .Current findings demonstrate that the annual mental health cost of relapsed patients is about 2 to 5 times higher than for non - relapsed patients , depending on whether the patients had relapsed in the 6 months prior to the 1-year study period .", "label": "", "metadata": {}, "score": "53.124672"}
{"text": "Disability progression was defined using the following criteria : One point increase from baseline in patients with Baseline Expanded Disability Status Scale ( EDSS ) score from 0 to 5.0 ; or half a point increase from Baseline in patients with Baseline EDSS score of 5.5 or above .", "label": "", "metadata": {}, "score": "53.157356"}
{"text": "Change From Baseline in Multiple Sclerosis Functional Composite ( MSFC ) Z - score [ Time Frame : Baseline , Month 24 and end of study ( up to approximately 54 months ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.561157"}
{"text": "With the implementation of Amendment 12 , all patients treated with Placebo in the fingolimod Core phase were switched to treatment with 0.5 mg fingolimod per day .", "label": "", "metadata": {}, "score": "53.625374"}
{"text": "The data used in the present study were from a longitudinal observational study of persons treated for schizophrenia in usual - care settings in the United States .", "label": "", "metadata": {}, "score": "53.713154"}
{"text": "Overall continuous treatment with CPA results in a reduced rate of relapse .Other trends suggested less treatment failure but more serious infections with continuous therapy but these were not statistically significant .", "label": "", "metadata": {}, "score": "53.742653"}
{"text": "In the Cox PH model analysis , the total dose remained the most important factor for predicting PSA normalization .CONCLUSIONS : These results are in accordance with the most recent results published after conformal EBT at the same 80 Gy level of dose .", "label": "", "metadata": {}, "score": "53.837616"}
{"text": "de Groot 2001 reports that treatment failure is more likely with continuous treatment with CPA .There are also some differences in results for relapse rate .", "label": "", "metadata": {}, "score": "54.071014"}
{"text": "Montgomery SA , \u00c5sberg M : A new depression scale designed to be sensitive to change .Br J Psychiatry 1979 , 134 : 382 - 389 .", "label": "", "metadata": {}, "score": "54.078094"}
{"text": "A screening test , such as My Profile Pediatric Assay , may help doctors predict a patient 's risk of relapse and plan better treatment for acute myeloid leukemia .", "label": "", "metadata": {}, "score": "54.10417"}
{"text": "Once remission is achieved , treatment is scaled back to maintenance therapy with lower doses of steroids and CPA is replaced by a less potent immunosuppressive , such as azathioprine ( AZA ) .", "label": "", "metadata": {}, "score": "54.258423"}
{"text": "View Article PubMed .Metzler C , Miehle N , Manger K , Iking - Konert C , de Groot K , Hellmich B , Gross WL , Reinhold - Keller E : Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener 's granulomatosis .", "label": "", "metadata": {}, "score": "54.295174"}
{"text": "PURPOSE : Increasing the dose to prostatic adenocarcinoma in conformal external beam therapy ( EBT ) has resulted in increased levels of PSA normalization and increased percentage of biochemical disease - free survival rates .", "label": "", "metadata": {}, "score": "54.297897"}
{"text": "A 6-month confirmed disability progression was defined as a 6-month sustained increase from Baseline in EDSS score .The EDSS quantifies disability in multiple sclerosis in 8 functional systems ; the score ranges from 0 ( normal ) to 10 ( death due to MS ) .", "label": "", "metadata": {}, "score": "54.42106"}
{"text": "Limited disease : Methotrexate 0.25 mg / kg / week to maximum of 25 mg / week .12 months after remission , MTX dose cut by 2.5 mg each month .", "label": "", "metadata": {}, "score": "54.57343"}
{"text": "Relapse of patients with schizophrenia is associated with substantial direct mental health costs that extend beyond the cost of hospitalization to other costly outpatient services and medication costs .", "label": "", "metadata": {}, "score": "54.624626"}
{"text": "Multivariate analysis identified biopsy Gleason score as the only independent preoperative predictor of recurrence .CONCLUSIONS : 67LR detection in PC biopsies was not a significant preoperative predictor of outcome after RP .", "label": "", "metadata": {}, "score": "54.677334"}
{"text": "View Article PubMed .Hsiao WC , Braun P , Dunn D , Becker ER : Resource - based relative values .An overview .JAMA 1988 , 260 ( 16 ) : 2347 - 2353 .", "label": "", "metadata": {}, "score": "54.725937"}
{"text": "Azathioprine vs Methotrexate for maintenance therapy .This study showed that the safety and efficacy profiles of Methotrexate and AZA are comparable .This data clearly places methotrexate as a better maintenance agent that MMF since it gave similar relapse rates to AZA .", "label": "", "metadata": {}, "score": "54.88396"}
{"text": "At the end of their 6 weeks of dosing , safety data for the group will be reviewed before the subsequent group receives a higher dosage .", "label": "", "metadata": {}, "score": "54.91015"}
{"text": "One hundred and twenty six patients treated to remission with standard doses of intravenous CPA and steroids were randomised to either AZA 2 mg / kg / d or MTX 0.3 mg / kg / wk increasing by 2.5 mg / week to a total of 25 mg / wk .", "label": "", "metadata": {}, "score": "55.02098"}
{"text": "The overall MSFC z - score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population .", "label": "", "metadata": {}, "score": "55.07959"}
{"text": "WGET 2005 .Etanercept 25 mg twice weekly by subcutaneous injection Immunosuppression as for control group .Twice weekly placebo injection .Severe disease : Cyclophosphamide 2 mg / kg / d .", "label": "", "metadata": {}, "score": "55.09064"}
{"text": "Official Title : . 24-month Double - blind , Randomized , Multicenter , Placebo - controlled , Parallel - group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod ( FTY720 )", "label": "", "metadata": {}, "score": "55.27623"}
{"text": "Primary outcome measures .Complete remission during the first 6 months after randomisation .Secondary outcome measures Adverse events .Jayne 2000 .IVIg 0.4 G / kg / d for 5 days .", "label": "", "metadata": {}, "score": "55.316338"}
{"text": "Clinicopathological preoperative and postoperative parameters , including 67LR expression , were correlated with each other and tested as predictors of biochemical relapse .RESULTS : 67LR was detected in 67.5 and 68.2 % of biopsies and RPs , respectively .", "label": "", "metadata": {}, "score": "55.318123"}
{"text": "There is no statistically significant difference between the groups .Risk of bias in included studies .A summary of quality measures is shown in Table 9 .", "label": "", "metadata": {}, "score": "55.37315"}
{"text": "The 4 patient groups were also compared on total cost and cost components for the subsequent year ( Additional file 2 ) .As expected , the RR group was the costliest and was about 5 times more costly than the group who did not relapse ( NN ) .", "label": "", "metadata": {}, "score": "55.409622"}
{"text": "67LR detection in RP specimens was an independent predictor of relapse .Multivariate analysis identified biopsy Gleason score as the only independent preoperative predictor of recurrence .", "label": "", "metadata": {}, "score": "55.424927"}
{"text": "CPA 15 mg / kg for 3 - 6 months ( 6 - 10 doses total ) .IV for remission induction .AZA for remission maintenance .", "label": "", "metadata": {}, "score": "55.48507"}
{"text": "Remission rates were equivalent but pulse treatment causes an increased risk of relapse ( 4 studies : RR 1.79 , CI 1.11 to 2.87 ) compared with continuous cyclophosphamide .", "label": "", "metadata": {}, "score": "55.619225"}
{"text": "There is currently no RCT data on the use of infliximab or other anti - TNF agents .There is some possibility that alternative agents may produce significantly different outcomes since their mechanism of action is distinct from that of etanercept .", "label": "", "metadata": {}, "score": "55.662865"}
{"text": "Primary outcome : treatment response .BVAS reduction of 50 % between entry and 3 months Secondary outcomes : fall in BVAS , CRP and ANCA , relapse frequency between 3 and 12 months , reduction in immunosuppressive drug doses and adverse effect .", "label": "", "metadata": {}, "score": "56.058193"}
{"text": "We conducted a retrospective review of medical records of 103 aquaporin-4 antibody - positive NMO and NMO spectrum disorder ( NMOSD ) patients treated with AZA .", "label": "", "metadata": {}, "score": "56.156624"}
{"text": "References .Weiden PJ , Olfson M : Cost of relapse in schizophrenia .Schizophr Bull 1995 , 21 ( 3 ) : 419 - 429 .", "label": "", "metadata": {}, "score": "56.227097"}
{"text": "The best results were obtained in post massage urine samples with a combination of GSTP1 , p14 , p16 , RAR\u03b22 and RASSF1A resulting in a sensitivity of 74 % and a specificity of 75 % .", "label": "", "metadata": {}, "score": "56.315445"}
{"text": "Study quality .The quality of studies to be included were assessed independently by GW and NW without blinding to authorship or journal of publication using the check list designed by the Cochrane Renal Group .", "label": "", "metadata": {}, "score": "56.35682"}
{"text": "Intensive outpatient service interventions , such as assertive community treatment , partial hospitalization programs , and programs for persons with co - occurring addictive disorders , which are designed for persons at risk of acute relapse , could help prevent or minimize relapses and attendant health care costs .", "label": "", "metadata": {}, "score": "56.535683"}
{"text": "Immunosuppression as for control group .After remission induction , AZA 2 mg / kg / d with Prednisolone 10 mg / d .BOTH GROUPS :", "label": "", "metadata": {}, "score": "56.601173"}
{"text": "View Article PubMed .Almond S , Knapp M , Francois C , Toumi M , Brugha T : Relapse in schizophrenia : costs , clinical outcomes and quality of life .", "label": "", "metadata": {}, "score": "56.694313"}
{"text": "The summary measure data were translated into number needed to treat ( NNT ) and number needed to harm ( NNH ) for the observed overall baseline risks .", "label": "", "metadata": {}, "score": "56.69714"}
{"text": "Methotrexate or Leflunomide are potential choices in remission maintenance therapy .Oral co - trimoxazole did not reduce relapses significantly in Wegener 's granulomatosis .Conclusions .", "label": "", "metadata": {}, "score": "56.75373"}
{"text": "New diagnoses of WG and MPA and renal involvement .Biopsy performed .Mortality was not significantly different between the two groups .There was evidence of statistically significant heterogeneity between the studies ( Figure 3 ) .", "label": "", "metadata": {}, "score": "56.77348"}
{"text": "Resource utilization and cost .Mental health resource utilization information for each participant was abstracted at baseline and every 6 months thereafter by trained examiners who used a medical record abstraction form developed for this study .", "label": "", "metadata": {}, "score": "56.77611"}
{"text": "Edited by : Scheffler RM , Rossiter LF .Greenwich , CT : JAI Press ; 1985 .Wrobel MV , Doshi J , Stuart BC , Briesacher B : Predictability of prescription drug expenditures for Medicare beneficiaries .", "label": "", "metadata": {}, "score": "57.24437"}
{"text": "Salkever DS , Slade EP , Karakus M , Palmer L , Russo PA : Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables .", "label": "", "metadata": {}, "score": "57.2712"}
{"text": "\" We believe that the addition of UAMS will help accomplish both of these objectives by broadening access to the trial .\" In the study , patients are dosed twice - weekly for 6 weeks followed by an observation period .", "label": "", "metadata": {}, "score": "57.302696"}
{"text": "Other remission induction studies .Inclusion and exclusion criteria , interventions and primary outcomes for these studies are detailed in tables 5 and 6 .Intravenous CPA for 6 months as 0.75 - 1.0 G / m 2 , modified depending on WCC nadir Iv MethylPrednisolone 0.5 G daily for three days both groups followed by oral prednisolone at 0.6 - 0.8 mg / kg / d for 4 weeks tapered by 5 mg / wk to 10 mg / d .", "label": "", "metadata": {}, "score": "57.419193"}
{"text": "Treatment generally was well tolerated .CONCLUSION : .A combination of prednisone and AZA is reasonably effective for the initial treatment of pure membranous lupus nephritis .", "label": "", "metadata": {}, "score": "57.457775"}
{"text": "Donohue J : Mental health in the Medicare Part D drug benefit : a new regulatory model ?Health Aff ( Millwood ) 2006 , 25 ( 3 ) : 707 - 719 .", "label": "", "metadata": {}, "score": "57.49552"}
{"text": "This will give further insight into this area with a population of patients which is likely to have a higher proportion of PR3 ANCA positive patients .", "label": "", "metadata": {}, "score": "57.502235"}
{"text": "Patients not entering remission were not randomised .Hiemstra 2009 .( IMPROVE ) .Newly diagnosed patients with WG , MPA or renal - limited vasculitis .", "label": "", "metadata": {}, "score": "57.532677"}
{"text": "The availability of non - invasive diagnostic molecular tests that could allow for a more precise identification of malignant prostate cells in asymptomatic men would be of great clinical value to improve PCa diagnosis .", "label": "", "metadata": {}, "score": "57.623436"}
{"text": "The actuarial 4 years biochemical no evidence of disease is 82.8 % for the entire population .Eight patients ( 4 % ) presented late grade 2 rectal complications but no grades 3 - 5 was observed .", "label": "", "metadata": {}, "score": "57.71261"}
{"text": "The use of MMF for remission induction is compared with CPA by Hu et al [ 21 ] .Thirty five patients with newly diagnosed ANCA associated vasculitis and moderate renal involvement were randomised to either 2 g / d MMF or standard intravenous CPA monthly pulses for 6 months .", "label": "", "metadata": {}, "score": "57.73239"}
{"text": "Vaul JH : DRG benchmarking study establishes national coding norms .Healthc Financ Manage 1998 , 52 ( 52 ) : 54 . D'AgostinoRB Jr : Propensity score methods for bias reduction in the comparison of a treatment to a non - randomized control group .", "label": "", "metadata": {}, "score": "57.73396"}
{"text": "Neurological function improved or stabilised in 78 % .Using Kaplan - Meyer curves , we estimate that 73 % , 58 % , 47 % and 33 % of patients will remain on AZA for longer than one , three , five and 10 years , respectively , after initiation of treatment .", "label": "", "metadata": {}, "score": "57.788986"}
{"text": "Approximately 400 patients enrolled at each of the 6 study sites .Enrollment was not contingent upon participants having been treated with any medication and was independent of concurrent psychiatric or medical conditions , use of concomitant medications , or substance use .", "label": "", "metadata": {}, "score": "57.834694"}
{"text": "Patient dosing in the study was initiated in November , 2011 at the Mayo Clinic in Rochester , Minnesota .Agirre , X. , Roman - Gomez , J. , Jimenez - Velasco , A. , Garate , L. et al .", "label": "", "metadata": {}, "score": "57.886475"}
{"text": "This question can not currently be answered by the randomised controlled trials .This systematic review data is currently the best available evidence to contribute to that debate .", "label": "", "metadata": {}, "score": "57.911846"}
{"text": "Am J Psychiatry 2006 , 163 ( 12 ) : 2080 - 2089 .View Article PubMed .Tunis SL , Faries DE , Nyhuis AW , Kinon BJ , Ascher - Svanum H , Aquila R : Cost - effectiveness of olanzapine as first - line treatment for schizophrenia : results from a randomized , open - label , 1-year trial .", "label": "", "metadata": {}, "score": "58.0382"}
{"text": "PubMed .Newhouse JP , Manning WG , Keeler EB , Sloss EM : Adjusting capitation rates using objective health measures and prior utilization .Health Care Financ Rev 1989 , 10 ( 3 ) : 41 - 54 .", "label": "", "metadata": {}, "score": "58.266983"}
{"text": "Six studies addressed the adjunctive use of plasma exchange with immunosuppression [ 29 - 33 ] .Inclusion criteria are summarised in Table 1 .The treatments tested in each of these studies differed in terms of both the standard immunosuppression and the protocol for plasma exchange ( Table 2 ) .", "label": "", "metadata": {}, "score": "58.271355"}
{"text": "Immunosuppression with prednisolone and CPA for generalized or methotrexate for limited disease was also given to both groups .Primary outcome was sustained remission with a BVAS / WG of 0 for at least 6 months .", "label": "", "metadata": {}, "score": "58.35144"}
{"text": "View Article PubMed .Ascher - Svanum H , Faries DE , Zhu B , Ernst FR , Swartz MS , Swanson JW : Medication adherence and long - term functional outcomes in the treatment of schizophrenia in usual care .", "label": "", "metadata": {}, "score": "58.671215"}
{"text": "Antibiotics for maintenance of remission .The use of co - trimoxazole to maintain remission was examined by Stegeman 1996 .This showed a benefit in reducing the risk of relapse but not on other outcomes .", "label": "", "metadata": {}, "score": "58.707127"}
{"text": "Discussion .Remission Induction .Plasma exchange as adjunctive therapy .This meta - analysis shows that plasma exchange confers a significant benefit to many patients with RPGN by reducing the risk of end stage renal failure at 12 months from diagnosis .", "label": "", "metadata": {}, "score": "58.796818"}
{"text": "View Article PubMed .Rondeau E , Levy M , Dosquet P , Ruedin P , Mougenot B , Kanfer A , Sraer JD : Plasma exchange and immunosuppression for rapidly progressive glomerulonephritis : prognosis and complications .", "label": "", "metadata": {}, "score": "58.8434"}
{"text": "Outcome measures .Mortality , kidney function , need for renal replacement therapy ( RRT ) , number of patients relapsing , adverse effects of each intervention .", "label": "", "metadata": {}, "score": "58.904408"}
{"text": "Panel A. Reduction of Clu and TGBFI proteins by gene specific siRNA knockdown assessed by Western blotting .YUMAC melanoma cells were untreated or treated with Aza ( 0.2 \u00b5M ) for 2 days followed by transient transfection with siRNA directed to Clu , TGFBI , or a mixture of the two , employing Alexa Fluor as a control , as indicated .", "label": "", "metadata": {}, "score": "58.92619"}
{"text": "Continuous score from the pre - specified classifier as a predictor of relapse after response to induction chemotherapy [ Time Frame : Up to 3 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.937645"}
{"text": "The use of IVIg demonstrated a therapeutic response in more patients at 3 months when compared with placebo .( 1 study ; risk ratio 2.33 ; 95 % confidence interval 1.18 to 4.61 ) .", "label": "", "metadata": {}, "score": "58.986763"}
{"text": "Defined as no clinical signs of vasculitis , improved or stable renal function , no active urinary sediment and BVAS score 0 .Changes in renal function , side effects .", "label": "", "metadata": {}, "score": "59.009888"}
{"text": "Group comparisons were performed using t tests for continuous variables and Mantel - Haenszel \u03c7 2 tests for categorical variables .Average total direct mental health costs and cost components were assessed during the study year and were compared between patients who relapsed ( in the 6 months preceding the 1-year follow - up ) and those who did not using propensity score adjusted bootstrap resampling .", "label": "", "metadata": {}, "score": "59.07721"}
{"text": "This study has a number of strengths , including the breadth of its clinical and economic measures and the diversity of the patient population across geographies and health care systems , suggesting high generalizability of the findings .", "label": "", "metadata": {}, "score": "59.12542"}
{"text": "View Article PubMed .Svarstad BL , Shireman TI , Sweeney JK : Using drug claims data to assess the relationship of medication adherence with hospitalization and costs .", "label": "", "metadata": {}, "score": "59.13075"}
{"text": "Panel A. Chromatograms showing CTNNB1 activating mutations in 501 mel cells ( GAC / CAC ) and YURIF tumor ( TCT / TGT ) ( marked by brackets and arrows ) , which lead to D32H and S33C mutations , respectively .", "label": "", "metadata": {}, "score": "59.269745"}
{"text": "Most patients ( 258 of 310 , or 83 % ) met 1 of these 4 criteria for relapse ; 31 ( 10 % ) met 2 ; 21 ( 7 % ) met 3 ; and no participant met all 4 .", "label": "", "metadata": {}, "score": "59.410023"}
{"text": "Electronic supplementary material .1471 - 244X-10 - 2-S1.DOC Additional file 1 : Table S1 .Baseline characteristics , direct annual mental health costs and cost components ( in 2000 US dollars ) for all 1,557 participants and for participants with and without prior relapse a .", "label": "", "metadata": {}, "score": "59.48277"}
{"text": "First is the potential for selection bias .Although propensity score matching was used to adjust for potential selection bias , such methods can not account for all potentially confounding factors ( i.e. , unmeasured variables ) .", "label": "", "metadata": {}, "score": "59.530434"}
{"text": "Levy JB , Winearls CG : Rapidly progressive glomerulonephritis : what should be first - line therapy ?Nephron 1994 , 67 : 402 - 407 .", "label": "", "metadata": {}, "score": "59.628242"}
{"text": "Panel D. The same cultures as in panel C were assessed for apoptosis employing the Caspase 3/7 assay .Bars indicate SD of 3 replicate wells .", "label": "", "metadata": {}, "score": "59.6644"}
{"text": "Mycophenolate for remission induction .The data currently available on this question remain sparse .The study by Hu et al is encouraging in that it does not show a reduction in remission induction with MMF .", "label": "", "metadata": {}, "score": "59.700703"}
{"text": "Jayne DR , Chapel H , Adu D , Misbah S , O'Donoghue D , Scott D , Lockwood CM : Intravenous immunoglobulin for ANCA - associated systemic vasculitis with persistent disease activity .", "label": "", "metadata": {}, "score": "59.704567"}
{"text": "All patients in the extension received blinded investigational drug : fingolimod 1.25 mg and 0.5 mg in capsules for oral administration once daily until the decision to discontinue the fingolimod 1.25 mg dose became effective and subsequently all patients were switched to open - label fingolimod 0.5 mg .", "label": "", "metadata": {}, "score": "59.72193"}
{"text": "Percentage of Participants Free of 6-month Confirmed Disability Progression at Month 24 and End of Study [ Time Frame : 24 months and end of study ( up to approximately 54 months ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "59.75402"}
{"text": "The study does however give some data on the use of Leflunomide and grounds for its clinical use .Final conclusions are difficult to draw .", "label": "", "metadata": {}, "score": "59.759228"}
{"text": "View Article PubMed .Salkever DS , Slade EP , Karakus MC : Employment retention by persons with schizophrenia employed in non - assisted jobs .", "label": "", "metadata": {}, "score": "59.783646"}
{"text": "Maintenance therapy continued for 12 months then withdrawn over 3 months .Trimethoprim - sulfamethoxazole 1600/320 daily recommended for WG patients for additional 2 years .", "label": "", "metadata": {}, "score": "59.833717"}
{"text": "Dickersin K , Scherer R , Lefebvre C : Identifying relevant studies for systematic reviews .BMJ 1994 , 309 : 1286 - 1291 .PubMed .", "label": "", "metadata": {}, "score": "59.866497"}
{"text": "A median of six sessions of each treatment were delivered .Immunosuppression was otherwise the same in the groups with standard CPA and prednisolone treatment .", "label": "", "metadata": {}, "score": "59.876785"}
{"text": "This investigation is currently under way as part of the PEXIVAS study run by the European Vasculitis Study Group .A cost effectiveness analysis is also required for the use of plasma exchange when compared with methylprednisolone .", "label": "", "metadata": {}, "score": "59.89917"}
{"text": "Molecular markers analyzed include Flt3-ITD , NPM1 , and MRA .Results are then correlated with each patient 's clinical data including patient 's age , race / ethnic background , gender , treatment received , and outcomes .", "label": "", "metadata": {}, "score": "59.91091"}
{"text": "View Article PubMed .de Groot K , Adu D , Savage CO : The value of pulse cyclophosphamide in ANCA - associated vasculitis : meta - analysis and critical review .", "label": "", "metadata": {}, "score": "59.91999"}
{"text": "Percentage of Participants Relapse - free up to End of Study [ Time Frame : From Baseline until the end of study ( up to approximately 54 months ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "59.96683"}
{"text": "Immunoadsorption , similarly , appears to have no benefit over the use of plasma exchange .Maintenance Therapy .Azathioprine vs CPA as maintenance therapy .", "label": "", "metadata": {}, "score": "60.07508"}
{"text": "Suicide attempts , for the previous 1-month period , were reported by the patients on the SCAP - Health Questionnaire ( SCAP - HQ ) , a validated measure developed for the study [ 12 ] .", "label": "", "metadata": {}, "score": "60.082"}
{"text": "Disease Extent Index ( DEI ) , BVAS , patient self assessment of quality of life ( SF-36 ) , cANCA titre , ESR , CRP .", "label": "", "metadata": {}, "score": "60.118984"}
{"text": "Data were drawn from a prospective , observational , noninterventional study of schizophrenia in the United States ( US - SCAP ) conducted between 7/1997 and 9/2003 .", "label": "", "metadata": {}, "score": "60.138607"}
{"text": "Immunosuppression as for control group .3 PE in first 5 days of at least 1 plasma volume .4 % Albumin as replacement .Median of six sessions .", "label": "", "metadata": {}, "score": "60.175194"}
{"text": "Panel C. DNMT1 expression at the end of 3-days treatment with Aza ( 0.2 \u00b5M ) .Cell extracts were subjected to Western blot with anti - DNMT1 antibodies .", "label": "", "metadata": {}, "score": "60.20227"}
{"text": "Panel A. Unsupervised hierarchical clustering of absolute intensity values .The vertical scale indicates 1-pearson 's correlation coefficients as a measure of similarity .", "label": "", "metadata": {}, "score": "60.246376"}
{"text": "This novel treatment described by Furuta 1998 gives some benefit when compared with three weeks of intravenous pulse methylprednisolone with a significantly lower SCr in treated patients .", "label": "", "metadata": {}, "score": "60.30053"}
{"text": "Jones R , Walsh M , Jayne D , for the European Vasculitis Study Group : Randomised trial of rituximab versus cyclophophamide for anca associated renal vasculitis : rituxvas [ abstract].", "label": "", "metadata": {}, "score": "60.381584"}
{"text": "Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase .In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day .", "label": "", "metadata": {}, "score": "60.466385"}
{"text": "One hundred and seventy four patients with newly diagnosed AAV were randomised after successful remission induction to receive either MMF or AZA [ 40 ] .", "label": "", "metadata": {}, "score": "60.485977"}
{"text": "Predictors of relapse .The predictors of relapse in the 1-year study for all patients and by prior relapse status are presented in Additional file 3 .", "label": "", "metadata": {}, "score": "60.66989"}
{"text": "They include a large number of uncontrolled studies .There was no attempt at meta - analysis .In the area of severe vasculitis with kidney involvement , there is a brief summary of the randomised trial data as included in this review .", "label": "", "metadata": {}, "score": "60.772568"}
{"text": "Thirty four patients with persistent disease activity were randomised to IVIg 0.4 g / kg / d for 3 days or to identical placebo injections .", "label": "", "metadata": {}, "score": "60.886345"}
{"text": "PXD101 ( 1 \u00b5M ) was added for 24 hrs before harvesting the cells .Notice differences in scale of absolute hybridization intensities in YUMAC and 501 mel cells .", "label": "", "metadata": {}, "score": "60.925514"}
{"text": "The study is lead on 75 patients with mean time follow - up of 12 months .Patient 's mean age is 20 years . 85 % of patients had a grade 3 left varicocele and 15 % a grade 2 left varicocele .", "label": "", "metadata": {}, "score": "60.973587"}
{"text": "( DOC 88 KB ) .1471 - 244X-10 - 2-S2.DOC Additional file 2 : Table S2 .Baseline sociodemographic and clinical characteristics , direct total annual mental health costs and cost components ( in 2000 US dollars ) for 4 groups that differed on relapse status prior to baseline .", "label": "", "metadata": {}, "score": "60.998425"}
{"text": "Intravenous immunoglobulin use for refractory vasculitis .The single RCT in this area suggests a short term benefit lasting up to 3 months .The treatment can be viewed as a therapy available to help induce remission but has little bearing on the longer term problem of remission maintenance .", "label": "", "metadata": {}, "score": "61.24538"}
{"text": "The data ruled out the DNA damage response , demonstrated the involvement of p21(Cip1 ) in a p53-independent manner , identified the TGFbeta pathway genes CLU and TGFBI as markers of sensitivity to decitabine and revealed an effect on histone modification as part of decitabine - induced gene expression .", "label": "", "metadata": {}, "score": "61.33618"}
{"text": "Prednisolone 20 mg / day and CPA 50 mg / day .SCr 4 weeks post treatment .Mortality .Stegmayr 1999 .Immunoadsorption : At least 2 plasma volumes were removed .", "label": "", "metadata": {}, "score": "61.48113"}
{"text": "There is a trend towards more patients requiring dialysis with the use of pulse CPA therapy .This is currently not statistically significant , but the fact remains that there were twice as many patients requiring dialysis after pulse therapy and that this effect is present in all studies .", "label": "", "metadata": {}, "score": "61.52066"}
{"text": "][ Designated as safety issue : No ] .ARR is the average number of relapses in a year calculated by negative binomial regression as the sum of confirmed relapses of all patients in the group divided by the sum of the number of days on study of all patients in the group and multiplied by 365.25 .", "label": "", "metadata": {}, "score": "61.54924"}
{"text": "It is clear that some patients with similar clinical features do not have this antibody and may have a different condition with different outcomes and prognosis .", "label": "", "metadata": {}, "score": "61.657555"}
{"text": "Consecutive patients with pure membranous lupus glomerulonephritis ( World Health Organization [ WHO ] Va and Vb ) from 4 regional hospitals were recruited for an open - label treatment trial consisting of prednisone and AZA .", "label": "", "metadata": {}, "score": "61.695927"}
{"text": "The data represent one of two sequence IDs with similar results .All other details as in .Panel B. Expression of p21 Cip1 and p53 , with \u03b2 - actin serving as a control .", "label": "", "metadata": {}, "score": "61.710632"}
{"text": "Inadequate contraception ; pregnancy ; previous malignancy ; hepatitis B antigenaemia or hepatitis C antibody or HIV infection ; other multi - system autoimmune disease ; circulating anti - GBM antibody or linear staining of GBM on histology ; life - threatening non - renal manifestations of vasculitis .", "label": "", "metadata": {}, "score": "61.715958"}
{"text": "As a result , accurate prediction of risk of relapse is critical to identifying persons who may need these intensive outpatient interventions .In essentially the only study of the costs of relapse for persons treated for schizophrenia in the United States , Weiden and Olfson estimated that , on a national level , almost $ 2 billion is spent annually for hospital readmissions of patients with schizophrenia [ 1 ] .", "label": "", "metadata": {}, "score": "61.765682"}
{"text": "They were also involved in preparing the resource utilization costing data of US - SCAP .XP performed the expanded statistical analyses , participated in the design of the study , the analytical plan , and the interpretation of the results .", "label": "", "metadata": {}, "score": "61.781925"}
{"text": "Other therapies including Mycophenolate mofetil ( MMF ) , anti - TNF therapy , leflunomide , methotrexate , anti - CD52 therapy , B cell depletion therapy and intravenous immunoglobulin have been suggested [ 16 - 18 ] but their place is not yet clear .", "label": "", "metadata": {}, "score": "61.932632"}
{"text": "Upon implementation of a protocol amendment , all patients taking placebo were switched to 0.5 mg fingolimod orally once a day .Drug : Placebo .", "label": "", "metadata": {}, "score": "62.026066"}
{"text": "The quality items to be assessed are allocation concealment , blinding , intention to treat analysis , and completeness of follow - up .Blinding was assessed for investigators , participants , outcome assessors and data analysis .", "label": "", "metadata": {}, "score": "62.04239"}
{"text": "View Article PubMed .Law MR , Soumerai SB , Ross - Degnan D , Adams AS : A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia .", "label": "", "metadata": {}, "score": "62.08543"}
{"text": "One , two , three stars refer to p - value less than 0.05 , 0.01 or 0.001 , respectively .We determined p - values by unpaired t - test ( Aza vs. Untreated ) .", "label": "", "metadata": {}, "score": "62.319088"}
{"text": "All other details as in .Middle panels show expression of p21 Cip1 and CLU after 2-days treatment with Aza ( 0.2 \u00b5M ) , where indicated ( + ) followed by 1-day incubation with PXD101 ( 1 \u00b5m ) .", "label": "", "metadata": {}, "score": "62.395927"}
{"text": "The importance of protein stability predicted from the results was validated by the synergistic effect of Bortezomib , a proteasome inhibitor , in enhancing the growth arrest of decitabine in otherwise resistant melanoma cells .", "label": "", "metadata": {}, "score": "62.437508"}
{"text": "Etanercept is not recommended for use in vasculitis .Leflunomide may be useful as maintenance therapy but requires further evaluation .IVIG is useful but only as a short term measure .", "label": "", "metadata": {}, "score": "62.493217"}
{"text": "Institutional Review Board approval was obtained , and informed consent was received from all participants .Participants were ages 18 or older and had been diagnosed with schizophrenia , schizoaffective , or schizophreniform disorder based on Diagnostic and Statistical Manual , Version 4 criteria .", "label": "", "metadata": {}, "score": "62.566807"}
{"text": "PubMed .Lapraik C , Watts R , Bacon P , Carruthers D , Chakravarty K , D'Cruz D , Guillevin L , Harper L , Jayne D , Luqmani R , Mooney J , Scott D : BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis .", "label": "", "metadata": {}, "score": "62.61152"}
{"text": "View Article PubMed .Weiden PJ , Kozma C , Grogg A , Locklear J : Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia .", "label": "", "metadata": {}, "score": "62.643894"}
{"text": "Primary .ii )Severe adverse events at 2 years .Secondary .All adverse events .Death .Prednisolone cumulative dose .CPA cumulative dose 3 .", "label": "", "metadata": {}, "score": "62.68704"}
{"text": "The surgical technique is briefly commented and the ( low ) morbidity of the operation is reviewed .They compare the results of RPV to those of external radiotherapy , watchful attitude or immediate hormonal treatment and they conclude in insisting on the benefit of the surgical approach as far as indications ( which are defined ) are strictly followed .", "label": "", "metadata": {}, "score": "62.86184"}
{"text": "Abnormal ASPP1 expression was associated with normal function of the tumor - suppressor gene TP53 in ALL .The analyses of 180 patients with ALL at diagnosis showed that the ASPP1 promoter was hypermethylated in 25 % of cases with decreased mRNA expression .", "label": "", "metadata": {}, "score": "62.92734"}
{"text": "View Article PubMed .Kerr PG , Chadban SJ , Atkins RC : Is there a role for plasma exchange in rapidly progressive glomerulonephritis ?Nephrology 2001 , 6 : 141 - 143 .", "label": "", "metadata": {}, "score": "62.93356"}
{"text": "The EDSS quantifies disability in multiple sclerosis in 8 functional systems ; the score ranges from 0 ( normal ) to 10 ( death due to MS ) .", "label": "", "metadata": {}, "score": "63.01266"}
{"text": "Lehman AF , Fischer EP , Postrado L , Delahanty J , Johnstone BM , Russo PA , Crown WH : The Schizophrenia Care and Assessment Program Health Questionnaire ( SCAP - HQ ) : an instrument to assess outcomes of schizophrenia care .", "label": "", "metadata": {}, "score": "63.141464"}
{"text": "This did not include the recent data on the use of pulse cyclophosphamide [ 20 ] , mycophenolate mofetil [ 21 ] , leflunomide [ 22 ] , methotrexate [ 23 ] , rituximab [ 24 , 25 ] and etanercept [ 26 ] .", "label": "", "metadata": {}, "score": "63.258034"}
{"text": "Though the rates of relapse with pulse CPA treatment are perhaps discouraging , this does not invalidate this mode of treatment .Pulse therapy still delivers a significantly lower total dose of CPA .", "label": "", "metadata": {}, "score": "63.39219"}
{"text": "Although immunosuppression has been successful , many questions remain unanswered in terms of dose and duration of therapy , the use of plasma exchange and the role of new therapies .", "label": "", "metadata": {}, "score": "63.399624"}
{"text": "Panel A. Growth arrest in response to Aza .Melanoma cells were untreated or treated with increasing concentrations of Aza for 2 days ( under line ) , released into regular growth medium and counted at 2 - 3 days intervals .", "label": "", "metadata": {}, "score": "63.619095"}
{"text": "Here and in all other Western blots numbers on the left mark the location of prestained protein markers in KDa , heavy and light frames designate Aza resistant and sensitive cells , respectively .", "label": "", "metadata": {}, "score": "63.695824"}
{"text": "In this study , we assessed 67LR detection in diagnostic biopsies as a predictor of biochemical relapse after RP .MATERIAL & METHODS : A total of 151 patients with clinically confined PC underwent RP .", "label": "", "metadata": {}, "score": "63.697998"}
{"text": "There were multiple methodological difficulties with this study addressed in the discussion section .Etanercept as adjunctive therapy .The use of etanercept as adjunctive therapy in AAV was investigated by the Wegener 's Granulomatosis Etanercept Trial Research Group [ 26 ] .", "label": "", "metadata": {}, "score": "63.8167"}
{"text": "Forest plot showing the risk ratio for induction of remission in patients treated with or without rituximab at 6 months and at study end .There is no significant difference between the groups .", "label": "", "metadata": {}, "score": "63.92402"}
{"text": "We are therefore reliant on the results of meta - analysis to attempt to provide an answer .This answer is less than perfect since it is a meta - analysis of results at different times post treatment across studies with significantly different protocols .", "label": "", "metadata": {}, "score": "63.97361"}
{"text": "Thus , age at disease onset and genetic factors are both likely to be important in determining clinical outcomes in aquaporin-4 disease .This has important implications for interpreting clinical neuromyelitis optica and neuromyelitis optica spectrum disorder studies , since clinical features and outcomes appear not to be generic across populations and may need to be tailored to individual groups .", "label": "", "metadata": {}, "score": "64.028625"}
{"text": "Four doses of Rituximab were given with 2 doses of CPA in the rituximab arm of the study .Primary end point was sustained remission at 6 months .", "label": "", "metadata": {}, "score": "64.107574"}
{"text": "The results are representative of two biological replicas .Panel C. BS sequencing results of TGFBI proximal promoter and first exon in normal human melanocytes ( NBMel ) and melanoma cells untreated ( control ) , and Aza ( 0.2 \u00b5M ) treated cells .", "label": "", "metadata": {}, "score": "64.14606"}
{"text": "Relapse was defined as having any of the following : psychiatric hospitalization , use of emergency services , use of a crisis bed , or a suicide attempt .", "label": "", "metadata": {}, "score": "64.206726"}
{"text": "There are , however , a number of differences .de Groot 2001 has utilised all the data from the Adu study .We have extracted the data only for patients without polyarteritis nodosa and with more than 0 % glomerular involvement .", "label": "", "metadata": {}, "score": "64.21193"}
{"text": "Remission Maintenance : discontinue CPA placebo and start oral azathioprine ( AZA ) placebo daily until Month 18 .Both groups : Iv MP 1 - 3 G then Prednisolone 1 mg / kg / d reduced to 40 mg month 1 , tapered to discontinue at the end of month 6 . rituximab placebo infusions once weekly for 4 weeks and CPA daily for 3 to 6 months Remission Maintenance : discontinue CPA and start AZA daily until Month 18 .", "label": "", "metadata": {}, "score": "64.406006"}
{"text": "Area under the receiver operating characteristic ( ROC ) curve of continuous score from the pre - specified classifier in predicting relapse after complete response to cytarabine- based induction chemotherapy [ Time Frame : Up to 3 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.444405"}
{"text": "Participants received placebo capsules orally once a day for up to 24 months during the core phase .In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day .", "label": "", "metadata": {}, "score": "64.6375"}
{"text": "View Article PubMed .Seo P , Stone JH : The antineutrophil cytoplasmic antibody - associated vasculitides .Am J Med 2004 , 117 : 39 - 50 .", "label": "", "metadata": {}, "score": "64.91944"}
{"text": "Dr. Salkever has served as a paid consultant to Eli Lilly and was an investigator on the US Schizophrenia Care and Assessment Program ( US - SCAP ) .", "label": "", "metadata": {}, "score": "64.92247"}
{"text": "Twenty two studies ( 1674 patients ) were included .Plasma exchange as adjunctive therapy significantly reduces the risk of end - stage kidney disease at 12 months ( five studies : RR 0.47 , CI 0.30 to 0.75 ) .", "label": "", "metadata": {}, "score": "64.92806"}
{"text": "View Article .Ann Rheum Dis 2009 , 68 : 310 - 317 .View Article PubMed .Menahem S , Hiremagalur B , Mudge D , Toussaint N , Walters G : The CARI guidelines .", "label": "", "metadata": {}, "score": "65.035904"}
{"text": "A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre - existing neurological abnormality , separated by at least 30 days from onset of a preceding clinical demyelinating event .", "label": "", "metadata": {}, "score": "65.03999"}
{"text": "A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre - existing neurological abnormality , separated by at least 30 days from onset of a preceding clinical demyelinating event .", "label": "", "metadata": {}, "score": "65.03999"}
{"text": "A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre - existing neurological abnormality , separated by at least 30 days from onset of a preceding clinical demyelinating event .", "label": "", "metadata": {}, "score": "65.03999"}
{"text": "Hu W , Liu C , Xie H , Chen H , Liu Z , Li L : Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal 26 involvement .", "label": "", "metadata": {}, "score": "65.06297"}
{"text": "Panel C. Apoptosis in response to low - dose Aza ( 0.2 \u00b5M ) measured by the Caspase - Glo 3/7 assay kit .Panel D. Apoptosis in response Aza ( 0.2 \u00b5M ) detected by immunofluorescence with anti - caspase-3 active rabbit antibodies ( green arrows point at green fluorescing apoptotic cells ) .", "label": "", "metadata": {}, "score": "65.095825"}
{"text": "Over a mean follow - up period of 90.4 + /- 59 months , 6 ( 19 % ) patients had relapse of nephritis ( proteinuric flare in 4 and nephritic flare in 2 ) .", "label": "", "metadata": {}, "score": "65.11339"}
{"text": "View Article PubMed .Pusey CD , Rees AJ , Evans DJ , Peters DK , Lockwood CM : Plasma exchange in focal necrotizing glomerulonephritis without anti - GBM antibodies .", "label": "", "metadata": {}, "score": "65.185074"}
{"text": "Panel A. Dose - dependent effects of Bortezomib on cell proliferation .YUMAC melanoma cells were seeded in 24 well plates , incubated with increasing concentration of Bortezomib for 72 h , and cells from triplicate wells were harvested and counted with Coulter counter .", "label": "", "metadata": {}, "score": "65.32441"}
{"text": "Other : diagnostic laboratory biomarker analysis .Correlative studies .Detailed Description : .OBJECTIVES : . Primary .To validate the accuracy of the My Profile Pediatric Assay to predict risk of relapse in pediatric patients with non - M3 acute myeloid leukemia ( AML ) who responded to cytarabine - based induction chemotherapy .", "label": "", "metadata": {}, "score": "65.37578"}
{"text": "Pregnant or nursing women .For inclusion in the extension phase patients should complete the 24 month core study with or without 24 months on study drug .", "label": "", "metadata": {}, "score": "65.38718"}
{"text": "Two authors independently assessed study quality and extracted data .Statistical analyses were performed using a random effects model and results expressed as risk ratio with 95 % confidence intervals for dichotomous outcomes or mean difference for continuous outcomes .", "label": "", "metadata": {}, "score": "65.430466"}
{"text": "We therefore took an integrative approach to better understand melanoma cell response to clinically relevant dose of decitabine and identify complementary targets for combined therapy .", "label": "", "metadata": {}, "score": "65.45952"}
{"text": "Ware JE Jr , Kosinski M , Keller SD : How to Score the SF-12 ?Physical and Mental Health Summary Scales .3rd edition .", "label": "", "metadata": {}, "score": "65.54151"}
{"text": "The use of lymphocytapheresis showed a highly significant reduction in SCr at four weeks ( 1 study ; MD -2.10 , 95 % CI -2.64 to -1.56 ) .", "label": "", "metadata": {}, "score": "65.667625"}
{"text": "Background .To assess the direct cost of relapse and the predictors of relapse during the treatment of patients with schizophrenia in the United States .", "label": "", "metadata": {}, "score": "65.73445"}
{"text": "View Article PubMed .Furuta T , Hotta O , Yusa N , Horigome I , Chiba S , Taguma Y : Lymphocytapheresis to treat rapidly progressive glomerulonephritis : a randomised comparison with steroid - pulse treatment .", "label": "", "metadata": {}, "score": "65.850464"}
{"text": "View Article PubMed .Lockwood CM , Rees AJ , Pearson TA , Evans DJ , Peters DK , Wilson CB : Immunosuppression and plasma - exchange in the treatment of Goodpasture 's syndrome .", "label": "", "metadata": {}, "score": "65.8965"}
{"text": "Proc Eur Dial Transplant Assoc 1981 , 18 : 493 - 502 .PubMed .Adu D , Pall A , Luqmani RA , Richards NT , Howie AJ , Emery P , Michael J , Savage CO , Bacon PA : Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis .", "label": "", "metadata": {}, "score": "65.90952"}
{"text": "Methods .Data source .Participants were recruited from diverse geographic areas , including the Northeast , Southwest , Mid - Atlantic , and West .", "label": "", "metadata": {}, "score": "65.9979"}
{"text": "Panel B. Expression of \u03b2 - catenin and MITF in melanoma cell strains relative to \u03b2 - actin .CTNNB1 mutation status for each cell strain is indicated at the top .", "label": "", "metadata": {}, "score": "66.091576"}
{"text": "On the multivariate analysis , methylation of the ASPP1 gene promoter was an independent poor prognosis factor in ALL patients .Our results demonstrate that decreased expression of ASPP1 in patients with ALL is due to an abnormal methylation o Affiliated with .", "label": "", "metadata": {}, "score": "66.17705"}
{"text": "PubMed .Kay SR , Fiszbein A , Opler LA : The positive and negative syndrome scale ( PANSS ) for schizophrenia .Schizophr Bull 1987 , 13 ( 2 ) : 261 - 276 .", "label": "", "metadata": {}, "score": "66.189445"}
{"text": "For dichotomous outcomes results were expressed as a risk ratio ( RR ) with 95 % confidence intervals ( CI ) .Data were pooled using the random effects model but the fixed effects model were also analysed to ensure robustness of the model chosen and susceptibility to outliers .", "label": "", "metadata": {}, "score": "66.20564"}
{"text": "There was no demonstrated difference in mortality or rate of relapse .Immunoadsorption and Lymphocytapheresis .Immunoadsorption was compared to plasma exchange in a single study [ 38 ] .", "label": "", "metadata": {}, "score": "66.244965"}
{"text": "View Article PubMed .Weiden PJ : Understanding and addressing adherence issues in schizophrenia : from theory to practice .J Clin Psychiatry 2007 , 68 ( Suppl 14 ) : 14 - 19 .", "label": "", "metadata": {}, "score": "66.356064"}
{"text": "1471 - 244X-10 - 2-S3.DOC Additional file 3 : Table S3 .Logistic regression analyses of relapse predictors for the 1,557 participants and by relapse status a .", "label": "", "metadata": {}, "score": "66.40676"}
{"text": "Panel B. Parallel cultures were tested for apoptosis with the Caspase 3/7 assay .Values are given as percent of control , i.e. , non - transfected cultures .", "label": "", "metadata": {}, "score": "66.52251"}
{"text": "Human anti - chimeric antibody testing Correlation of B cells with disease activity Change in ANCA and disease activity Histopathology predictors of outcome .Stone 2009 .", "label": "", "metadata": {}, "score": "66.5349"}
{"text": "Further details about US - SCAP have been reported elsewhere [ 10 , 11 ] .Analytical sample .Of 2,327 patients in the US - SCAP , 1,817 ( 78 % ) completed a 1-year follow - up interview .", "label": "", "metadata": {}, "score": "66.53545"}
{"text": "Forest plot showing the risk of requiring renal replacement therapy at 3 , 6 or 12 months after induction treatment for vasculitis in patients treated with and without plasma exchange .", "label": "", "metadata": {}, "score": "66.644485"}
{"text": "Late toxicity is identical but our urinary toxicity is within the less favourable and rectal toxicity within the most favourable results .We can postulate that while inducing very high hyperdosage regions ( V150 ) mainly focused on the peripheral zone , most of the Bt techniques consist of a more ablative treatment .", "label": "", "metadata": {}, "score": "66.645386"}
{"text": "This study highlights the need to explore pulsed dose rate therapies , permanent implant and new available radioisotopes such as ( 169)Ytterbium that will offer the safety of low and lower dose rates .", "label": "", "metadata": {}, "score": "66.707405"}
{"text": "Loading dose of 100 mg / d for 3 days , followed by 20 mg / d from day 4 to end of week 4 .", "label": "", "metadata": {}, "score": "66.777664"}
{"text": "A digital rectal examination ( DRE ) and the measurement of serum prostate specific antigen ( PSA ) levels are the current standards for PCa early detection .", "label": "", "metadata": {}, "score": "67.33005"}
{"text": "Leflunomide was shown to be superior to methotrexate for relapse prevention in a time to event analysis in Metzler 2007 .Our analysis suggests Leflunomide may be superior but does not reach statistical significance ( 1 study ; risk ratio 0.50 ; 95 % confidence interval 0.22 to 1.11 ) .", "label": "", "metadata": {}, "score": "67.40528"}
{"text": "The importance of 67LR expression was evaluated according to the intensity and extent of the staining .Preoperative and postoperative clinicopathological parameters , including 67LR expression , were correlated with each other and tested as predictors of biochemical relapse .", "label": "", "metadata": {}, "score": "67.49415"}
{"text": "Heterogeneity of 67LR expression and biopsy sampling errors most likely represented the main raisons for discordant prognostic results depending on whether 67LR expression was evaluated either in biopsies or in RPs .", "label": "", "metadata": {}, "score": "67.792366"}
{"text": "It is therefore not clear whether plasma exchange has any impact in patients whose kidney failure is not severe .There was little statistical heterogeneity in all outcomes of these studies with the single exception of SCr at 12 months .", "label": "", "metadata": {}, "score": "67.92703"}
{"text": "However , many patients discontinue AZA over time and this seems to reflect poor tolerability more than lack of efficacy .[ Show abstract ] [ Hide abstract ] ABSTRACT : Neuromyelitis optica and neuromyelitis optica spectrum disorders have been recently associated with the disease - specific autoantibody aquaporin-4 , thought to be pathogenic .", "label": "", "metadata": {}, "score": "67.962524"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Azathioprine ( AZA ) is a common immunosuppressive drug used for relapse prevention in neuromyelitis optica ( NMO ) .", "label": "", "metadata": {}, "score": "68.14898"}
{"text": "( NCT01201356 ; initiated in September 2010 ) .Male and female patients between ages 18 - 55 with a diagnosis of multiple sclerosis .Patients with a relapsing - remitting disease course .", "label": "", "metadata": {}, "score": "68.153824"}
{"text": "Percentage of Participants Relapse - free up to Month 24 [ Time Frame : 24 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "68.242386"}
{"text": "Tervaert JW , Stegeman CA , Kallenberg CG : Novel therapies for anti - neutrophil cytoplasmic antibody - associated vasculitis .Curr Opin Nephrol Hypertens 2001 , 10 : 211 - 217 .", "label": "", "metadata": {}, "score": "68.40015"}
{"text": "They expose the reasons which have led them to adopt this kind of treatment and the reasons explaining a nearly exponential increase of the frequency of the operation during the last 5 years .", "label": "", "metadata": {}, "score": "68.43767"}
{"text": "de Groot 2001 is a review of the data relating to the use of pulse or continuous CPA for induction of remission of ANCA - associated vasculitis and includes a meta - analysis of the randomised controlled trial data [ 13 ] .", "label": "", "metadata": {}, "score": "68.5363"}
{"text": "Further studies are in progress to validate the assay across multiple centers .BACKGROUND AND PURPOSE : To evaluate on 201 locally advanced prostatic cancers prospectively treated in a phase II trial , the efficacy of a combination of external beam radiotherapy ( 39.6 Gy ) and ( 192)Ir low dose rate brachytherapy ( Bt ) ( 40 - 45 Gy ) .", "label": "", "metadata": {}, "score": "68.60736"}
{"text": "Pulse versus continuous cyclophosphamide .Four studies assessed pulse versus continuous administration of CPA [ 20 , 34 - 36 ] .Systemic , rather than specifically renal , vasculitis was included .", "label": "", "metadata": {}, "score": "68.61799"}
{"text": "Introduction : The best outcome for patients with prostate cancer ( PCa ) is seen for those treated at an early stage of the disease .", "label": "", "metadata": {}, "score": "68.756065"}
{"text": "Comparison with other reviews .Two previous reviews have covered some of the subjects addressed in this review .Bosch 2007 provides a broad review of the treatment of ANCA associated vasculitis [ 43 ] .", "label": "", "metadata": {}, "score": "68.799965"}
{"text": "Age at disease onset appeared to be an important predictor of disability type .Young - onset patients in the UK , but not the Japanese cohort , commonly presenting with optic neuritis , had a high risk of visual disability while older patients in both cohorts had a high risk of motor disability , regardless of their onset symptom .", "label": "", "metadata": {}, "score": "68.83895"}
{"text": "Jennette J , Falk R : Renal and systemic vasculitis .In Comprehensive clinical nephrology .Mosby 2nd edition .Edited by : Johnson R , Feehally J. 2003 , 341 - 357 .", "label": "", "metadata": {}, "score": "68.94388"}
{"text": "The heavy line on the ordinate represent the levels of TGFBI- transcript levels in adult melanocytes .The data represent one sequence ID .All other details as in .", "label": "", "metadata": {}, "score": "69.00404"}
{"text": "Leflunomide was compared with methotrexate for remission maintenance [ 22 ] .Fifty four patients successfully treated to remission with prednisolone and CPA , were randomised to either leflunomide or methotrexate treatment .", "label": "", "metadata": {}, "score": "69.05735"}
{"text": "Stegeman CA , Tervaert JW , de Jong PE , Kallenberg CG : Trimethoprim - sulfamethoxazole ( co - trimoxazole ) for the prevention of relapses of Wegener 's granulomatosis .", "label": "", "metadata": {}, "score": "69.10635"}
{"text": "View Article PubMed .Bosch X , Guilabert A , Espinosa G , Mirapeix E : Treatment of antineutrophil cytoplasmic antibody associated vasculitis : a systematic review .", "label": "", "metadata": {}, "score": "69.155945"}
{"text": "Dialysis .Death .Rituximab vs cyclophosphamide alone for remission induction .Two studies have been published in abstract form , the RITUXVAS and RAVE studies [ 25 , 24 ] .", "label": "", "metadata": {}, "score": "69.473785"}
{"text": "Rituximab vs cyclophosphamide alone for remission induction .The RITUXVAS and RAVE studies are two well designed studies showing that Rituximab is equivalent to CPA therapy for remission induction whilst side effects occur at a similar frequency albeit possibly in a smaller number of patients with rituximab .", "label": "", "metadata": {}, "score": "69.53062"}
{"text": "D . , The Medstat Group , Inc. , Washington , DC ; Rosenheck RA , M.D . , West Haven Veterans Administration Medical Center ( VAMC ) and the Connecticut Mental Health Center ( CMHC ) , West Haven , CT ; Russo P , Ph.D. , M.S.W. , R.N . , ( previously )", "label": "", "metadata": {}, "score": "69.63762"}
{"text": "The basal levels of CLU transcripts in YUMAC were about 50 fold higher relative to 501 mel melanoma cells , in agreement with low protein levels ( data not shown ) .", "label": "", "metadata": {}, "score": "69.75476"}
{"text": "Am J Kidney Dis 1992 , 20 : 261 - 269 .PubMed .Gl\u00f6ckner WM , Sieberth HG , Wichmann HE , Backes E , Bambauer R , Boesken WH , Bohle A , Daul A , Graben N , Keller F : Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis : a controlled , multi - center study .", "label": "", "metadata": {}, "score": "69.914276"}
{"text": "The demographics of the included patients are included in the review in the Cochrane Library .The numbers of studies identified by the search and subsequently excluded are documented in the flow diagram in Figure 1 .", "label": "", "metadata": {}, "score": "70.145386"}
{"text": "D . , Boston University and Community Mental Health Centers in Denver , CO ; Hoff R , Ph.D. , M.P.H . , West Haven Veterans Administration Medical Center ( VAMC ) and the Connecticut Mental Health Center ( CMHC ) , West Haven , CT ; Hough R , Ph .", "label": "", "metadata": {}, "score": "70.18227"}
{"text": "The Wegener 's Granulomatosis Etanercept Trial ( WGET )Research Group : Etanercept plus standard therapy for Wegener 's granulomatosis .N Engl J Med 2005 , 352 : 351 - 361 .", "label": "", "metadata": {}, "score": "70.18608"}
{"text": "Endoscopic procedures definitely improved or cured 82 % of the patients at a mean followup of 51 months , during which neither early nor late complications were noted .", "label": "", "metadata": {}, "score": "70.29731"}
{"text": "Trimethoprim - sulfamethoxazole 320/1600 daily recommended for WG patients for additional 2 years .Methotrexate 0.3 mg / kg / week , increasing every week by 2.5 mg to 25 mg / week .", "label": "", "metadata": {}, "score": "70.42879"}
{"text": "New diagnosis of systemic WG diagnosed clinically based on the presence of multi - organ involvement .Mono - visceral involvement representing a potential risk or severe morbidity of fatality .", "label": "", "metadata": {}, "score": "70.492836"}
{"text": "View Article PubMed .Arthritis Rheum 1997 , 40 : 2187 - 2198 .View Article PubMed .Haubitz M , Schellong S , G\u00f6bel U , Schurek HJ , Schaumann D , Koch KM , Brunkhorst R : Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody - associated vasculitis and renal involvement : a prospective , randomized study .", "label": "", "metadata": {}, "score": "70.55621"}
{"text": "Panel E. SFRP1 transcripts in melanoma cell strains as assessed by the oligonucleotide array hybridization .The data represent one of two sequence IDs with similar results .", "label": "", "metadata": {}, "score": "70.62493"}
{"text": "Heterogeneity was analysed using \u03c7 2 test on N-1 degrees of freedom , with an \u03b1 a of 0.05 used for statistical significance and with the I 2 test ( Higgins 2003 ) .", "label": "", "metadata": {}, "score": "70.86964"}
{"text": "Six month results are reported in abstract form only .Primary outcome was disease remission in the absence of prednisolone therapy at 6 months .The results reported here are disease remission at 6 months on Prednisolone 10 mg / d or less .", "label": "", "metadata": {}, "score": "70.89842"}
{"text": "Current studies suggest that pulse CPA may leave more patients on dialysis unnecessarily .The use of MMF for remission induction is being examined in the current MYCYC study by the European Vasculitis Study group .", "label": "", "metadata": {}, "score": "70.909706"}
{"text": "Parallel cultures were untreated or treated with Aza ( 0.2 \u00b5M ) for 2 days followed by transient transfection with three different CTNNB1 siRNA or with Alexa Fluor as a control for one day .", "label": "", "metadata": {}, "score": "71.096825"}
{"text": "Secondary outcomes were any adverse event , severe adverse event , relapse , relapse free survival , event free survival and quality of life .Both treatments gave similar results for all the secondary outcomes .", "label": "", "metadata": {}, "score": "71.097885"}
{"text": "PCa was found in 51 % of the patients .Histological diagnosis of the biopsies was compared to methylation results in urine from 102 samples ( 89 % success rate due low DNA yields for 12 samples ) .", "label": "", "metadata": {}, "score": "71.22244"}
{"text": "The single study of Leflunomide suggests that this may be an appropriate treatment for patients who are intolerant of Azathioprine .There are problems with interpretation and extrapolation from this study .", "label": "", "metadata": {}, "score": "71.246284"}
{"text": "D . , ( previously ) Johns Hopkins University , Department of Health Policy and Management , Baltimore , MD ; Saunders T , M.S . , Drug Abuse and Mental Health Program Office of District 7 and University of South Florida 's Florida Mental Health Institute , Orlando , FL ; Shern D , Ph .", "label": "", "metadata": {}, "score": "71.255875"}
{"text": "The RAVE study distinguished itself by being a randomised blinded study involving the use of placebo rituximab infusions and CPA and AZA tablets .One hundred and ninety seven patients with severe AAV were recruited .", "label": "", "metadata": {}, "score": "71.26925"}
{"text": "CPA continued for 8 weeks or longer if ANCA positive . CrCl and SCr .Responder ( CrCl improved by at least 20 ml / min or patient could leave dialysis ) .", "label": "", "metadata": {}, "score": "71.35077"}
{"text": "Oncogene 2006 ; 25 : 1862 - 1870 .Abstract .We have analyzed the regulation and expression of ASPP members , genes implicated in the regulation of the apoptotic function of the TP53 tumor - suppressor gene , in acute lymphoblastic leukemia ( ALL ) .", "label": "", "metadata": {}, "score": "71.416534"}
{"text": "they would be excluded from the Extension Phase .Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "71.44713"}
{"text": "Pulse cyclophosphamide results in an increased risk of relapse when compared to continuous oral use but a reduced total dose .Whilst cyclophosphamide is standard induction treatment , rituximab and mycophenolate mofetil are also effective .", "label": "", "metadata": {}, "score": "71.83589"}
{"text": "Only three reported blinding of patient , physicians and outcome assessors .The majority of reports do not contain adequate data to clearly indicate the risk of bias .", "label": "", "metadata": {}, "score": "71.85252"}
{"text": "Decitabine , an epigenetic modifier that reactivates genes otherwise suppressed by DNA promoter methylation , is effective for some , but not all cancer patients , especially those with solid tumors .", "label": "", "metadata": {}, "score": "71.923134"}
{"text": "View Article PubMed .Andlin - Sobocki P , J\u00f6nsson B , Wittchen HU , Olesen J : Cost of disorders of the brain in Europe .", "label": "", "metadata": {}, "score": "72.23141"}
{"text": "Cell viability was assessed with the CellTiter - Glo \u00ae Luminescent Cell Viability Assay .Data are presented as percent of control , non - treated cells .", "label": "", "metadata": {}, "score": "72.3167"}
{"text": "PubMed .J Am Soc Nephrol 2007 , 18 : 2180 - 2188 .View Article PubMed .Mauri J , Gonzalez M , Poveda R : Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonphritis .", "label": "", "metadata": {}, "score": "72.40994"}
{"text": "Curr Opin Rheumatol 2008 , 20 : 55 - 60 .View Article PubMed .Bolton WK , Sturgill BC : Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis .", "label": "", "metadata": {}, "score": "72.49028"}
{"text": "Either new or established disease .None stated .Pagnoux 2008 .Patients over 18 years old .Newly diagnosed Wegener 's Granulomatosis and Microscopic Polyangiitis .", "label": "", "metadata": {}, "score": "72.508255"}
{"text": "\" We are very pleased to have added UAMS as a clinical site along with the Mayo Clinic in order to accelerate patient enrollment and increase awareness of the SNS01-T study , \" stated Leslie J. Browne , Ph .", "label": "", "metadata": {}, "score": "72.62352"}
{"text": "D . , Center for Research on Child and Adolescent Mental Health Services , San Diego , CA ; Dunn LA , M.D . , Duke University Medical Center Department of Psychiatry , Durham , NC ; Gallucci G , M.D . , ( previously ) Johns Hopkins Bayview Medical Center and the University of Maryland Medical Systems , Baltimore , MD ; Garcia P , Ph .", "label": "", "metadata": {}, "score": "72.675316"}
{"text": "OBJECTIVES : Reliable prognostic indicators are needed for a better pretherapeutic assessment of the agressiveness of organ - confined prostate cancer ( PC ) lesions .", "label": "", "metadata": {}, "score": "72.890656"}
{"text": "Detailed Description : .This randomized , multicenter , parallel - group study consisted of 2 phases : a 24-month double - blind , randomized , multicenter , placebo - controlled , parallel - group study and an Extension phase which consisted of a dose - blinded period and an open - label period .", "label": "", "metadata": {}, "score": "73.01706"}
{"text": "CPA treatment was given for three months , approximately six months , one and two years in the four relevant studies .This difference may account for the significant level of statistical heterogeneity detected in mortality and the incidence of serious infections .", "label": "", "metadata": {}, "score": "73.18671"}
{"text": "End stage renal failure unless active extra - renal disease requires treatment Inability for informed consent .All patients received identical remission induction therapy .Pulse MP 15 mg / kg for 3 days .", "label": "", "metadata": {}, "score": "73.27164"}
{"text": "View Article PubMed .Stegmayr BG , Almroth G , Berlin G , Fehrman I , Kurkus J , Norda R , Olander R , Sterner G , Thysell H , Wikstr\u00f6m B , Wir\u00e9n JE : Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis .", "label": "", "metadata": {}, "score": "73.44342"}
{"text": "Rifle G , Chalopin JM , Zech P , Deteix P , Ducret F , Vialtel P , Cordonnier D : Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma - exchanges .", "label": "", "metadata": {}, "score": "73.56987"}
{"text": "( RITUXVAS ) .Rituximab , 375 mg / m 2 IV once a week for 4 weeks ( i.e. 4 doses total ) , with 2 doses of cyclophosphamide 15 mg / kg , 2 weeks apart given with the 1 st and 3 rd rituximab dose .", "label": "", "metadata": {}, "score": "73.62213"}
{"text": "Any cytotoxic drug within previous year .Co- existence of another systemic autoimmune disease , e.g. SLE .Hepatitis B or Hepatitis C infection HIV positivity .", "label": "", "metadata": {}, "score": "73.62561"}
{"text": "Pulse CPA 0.6 G / m 2 , 3 doses at 2 week intervals then every 3 weeks until remission , 3 further consolidation doses at 3 week intervals .", "label": "", "metadata": {}, "score": "73.637115"}
{"text": "View Article PubMed .Welch WP : Medicare capitation payments to HMOs in light of regression towards the mean in health care costs .In Advances in Health Economics and Health Services Research .", "label": "", "metadata": {}, "score": "73.640724"}
{"text": "Prednisolone as per methotrexate group .Methotrexate : 7.5 mg / week weeks 1 to 4 . 15 mg / week for weeks 5 to 8 .", "label": "", "metadata": {}, "score": "73.73794"}
{"text": "( # 1 or # 2 or # 3 or # 4 or # 5 or # 6 or # 7 or # 8) .exp WEGENER 'S GRANULOMATOSIS/ . exp Antibodies , Antineutrophil Cytoplasmic / or exp Vasculitis / or exp Glomerulonephritis / or exp Polyarteritis Nodosa/ .", "label": "", "metadata": {}, "score": "73.8646"}
{"text": "This is an updated version containing the latest RCT data in several areas not previously published as part of this review .Most significant is the new data on pulse versus continuous cyclophosphamide discussed above .", "label": "", "metadata": {}, "score": "73.9837"}
{"text": "The aim is to avoid the pelvic bone shield while a good focalization of the stone is realized .From June 1989 to March 1991 , 35 patients were treated for distal ureteric stones by ESWL in this original positioning .", "label": "", "metadata": {}, "score": "74.04262"}
{"text": "Aggregate Annualized Relapse Rate ( ARR ) Estimate up to Month 24 [ Time Frame : 24 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "74.33183"}
{"text": "JC was involved in the design of the study , adjudication on disagreements in data analysis and editing of draft and final versions of the paper .", "label": "", "metadata": {}, "score": "74.442474"}
{"text": "SCr : .Serum Creatinine .SMD : . standardised mean difference .TNF : .Tumour necrosis factor .WG : .Wegener 's Granulomatosis .", "label": "", "metadata": {}, "score": "74.447235"}
{"text": "Objectives .To evaluate the benefits and harms of any intervention used for the treatment of renal vasculitis in adults .Studies .All RCTs and quasi - RCTs looking at any intervention used for the treatment of renal vasculitis in adults .", "label": "", "metadata": {}, "score": "74.447754"}
{"text": "The treatment of systemic and renal vasculitis involves the use of steroids in combination with other non - steroid agents , most commonly , cyclophosphamide ( CPA ) [ 5 , 1 ] to induce remission of disease .", "label": "", "metadata": {}, "score": "74.46434"}
{"text": "Results .Description of studies .Twenty two studies ( 28 references , 1674 participants ) were identified as eligible for inclusion in this review .", "label": "", "metadata": {}, "score": "74.471436"}
{"text": "Competing interests .The authors declare that they have no competing interests .Authors ' contributions .GW was involved in the design of the study , conducted the literature searches , obtained and analysed studies and wrote the draft and final versions of the paper .", "label": "", "metadata": {}, "score": "74.47453"}
{"text": "In case of disseminated disease , hormonal manipulations remain the treatment of choice .In that field , many new drugs have been designed to allow medical castration with less complications , especially regarding sexual potency .", "label": "", "metadata": {}, "score": "74.49987"}
{"text": "We have studied relapse as related to the initial number of patients whereas de Groot 2001 have recorded relapses as related to achieved remissions .With the higher treatment failure figures in the continuous arm , de Groot 2001 does not show a significant difference in the overall relapse rate .", "label": "", "metadata": {}, "score": "74.6413"}
{"text": "Prostatic cancer ( PC ) became the first diagnosed cancer in western men and is the second leading cause of cancer death in men .Wide utilisation of serum PSA and free PSA measurements , identifies patients requiring transrectalultrasonography ( TRUS ) and TRUS guided biopsies .", "label": "", "metadata": {}, "score": "74.86751"}
{"text": "Co- trimoxazole 960 mg twice daily .Placebo .Death .Remission .Jayne 2003 .CPA 1.5 mg / kg / d from remission .", "label": "", "metadata": {}, "score": "74.89848"}
{"text": "Schizophrenia is a severe and chronic mental illness characterized by recurring relapses that may require inpatient hospitalization .Costs associated with treatment received consequent to relapse may account for the largest share of treatment costs in schizophrenia [ 1 - 4 ] , which is one of the most expensive to treat psychiatric conditions [ 5 ] .", "label": "", "metadata": {}, "score": "75.4754"}
{"text": "Methods .We searched the Cochrane Central Register of Controlled Trials , the Cochrane Renal Group Specialised Register , MEDLINE and EMBASE to June 2009 .", "label": "", "metadata": {}, "score": "75.65765"}
{"text": "Authors ' contributions .HA - S conceived of the study , participated in its design , the analytical plan , the interpretation of the results , and helped write the manuscript .", "label": "", "metadata": {}, "score": "76.00452"}
{"text": "Clinical success is obtained in 87 % of the cases and the doppler control is normal in 80 % of the cases .We have 9 % of minor complications , and no major complication .", "label": "", "metadata": {}, "score": "76.03198"}
{"text": "Forest plot showing the risk ratio of end stage renal failure in patients treated with either pulse or continuous cyclophosphamide therapy at 3 , 6 or 12 months and at study end .", "label": "", "metadata": {}, "score": "76.03219"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01438138 . childhood acute myeloid leukemia in remission recurrent childhood acute myeloid leukemia untreated childhood acute myeloid leukemia and other myeloid malignancies childhood acute basophilic leukemia childhood acute eosinophilic leukemia childhood acute erythroleukemia ( M6 ) childhood acute megakaryocytic leukemia ( M7 ) .", "label": "", "metadata": {}, "score": "76.142456"}
{"text": "DEF participated in the design of the study , the analytical plan , the interpretation of the results , and assisted in drafting the manuscript .", "label": "", "metadata": {}, "score": "76.18496"}
{"text": "Forest plot showing the risk of death at 3 , 6 and 12 months and 2 and 5 years and at final follow - up in patients treated with pulse or continuous cyclophosphamide .", "label": "", "metadata": {}, "score": "76.310196"}
{"text": "We investigated clinical outcomes and prognostic characteristics of 106 aquaporin-4 antibody - seropositive patients from the UK and Japan .Data were collected largely retrospectively through review of case records .", "label": "", "metadata": {}, "score": "76.34545"}
{"text": "D . , University of California at San Francisco , Department of Psychiatry , San Francisco , CA ; Slade E , Ph .D . , ( previously ) Johns Hopkins University , Department of Health Policy and Management , Baltimore , MD ; Swanson J , Ph .", "label": "", "metadata": {}, "score": "76.376785"}
{"text": "These conditions include the anti - neutrophil cytoplasmic antibody ( ANCA ) associated vasculitides ( AAV ) , anti - glomerular basement membrane ( anti - GBM ) disease and idiopathic RPGN [ 1 ] .", "label": "", "metadata": {}, "score": "76.59694"}
{"text": "Its components ( the table and the orientation of the semi - ellipsoid reflector ) are adapted for the treatment of kidney or lumbar ureter stones .", "label": "", "metadata": {}, "score": "76.67511"}
{"text": "The aim of this study is to judge the effectiveness of the new treatment of varicoceles , introduced in 1987 by Tauber : the antegradal scrotal sclerotherapy of varicoceles .", "label": "", "metadata": {}, "score": "76.81688"}
{"text": "Foreign language studies were not excluded .Participants .All adults suffering from an episode of AKF and/or proteinuria and haematuria with a kidney biopsy showing severe acute glomerulonephritis with crescents , glomerular necrosis or other histological evidence of vasculitis .", "label": "", "metadata": {}, "score": "76.822334"}
{"text": "Competing interests .Dr. Ascher - Svanum is a full - time employee of Eli Lilly and Company .Drs .Zhu , Faries , Peng , and Conley are full - time employees of Lilly USA , LLC .", "label": "", "metadata": {}, "score": "76.836586"}
{"text": "Walters G , Willis NS , Craig JC : Interventions for renal vasculitis in adults .Cochrane Database Syst Rev 2008 , CD003232 .Ann Intern Med 2009 , 150 : 670 - 680 .", "label": "", "metadata": {}, "score": "77.076645"}
{"text": "Acknowledgements .The US - SCAP study and its report were supported by Eli Lilly and Company , Indianapolis , IN , USA and administered by the Medstat Group .", "label": "", "metadata": {}, "score": "77.12875"}
{"text": "Bars indicate 20 \u00b5m .The histogram shows percent apoptotic cells measured by counting the number of active caspase-3 positive green fluorescing cells in 10 independent microscopic fields representing about 800 cells each .", "label": "", "metadata": {}, "score": "77.41519"}
{"text": "Fourth International Cochrane Colloquium ; Adelaide 1996 .Cole E , Cattran D , Magil A , Greenwood C , Churchill D , Sutton D , Clark W , Morrin P , Posen G , Bernstein K : A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis .", "label": "", "metadata": {}, "score": "77.46596"}
{"text": "Thirty - eight patients ( 31 women and 7 men ) were studied .The mean age was 35.0 + /- 9.2 years , and the duration of systemic lupus erythematosus was 48.5 + /- 59 months .", "label": "", "metadata": {}, "score": "77.80159"}
{"text": "Inclusion criteria are summarised in Table 3 .The treatment regimens in these studies also differed , as summarised in Table 4 .Wegener 's granulomatosis , classical polyarteritis nodosa and microscopic polyarteritis diagnosed by histological or radiological evidence .", "label": "", "metadata": {}, "score": "77.83786"}
{"text": "Forest plot showing the risk ratio of achieving remission in patients treated with pulse or continuous cyclophosphamide at various time points .There is no change in the rate of remission with pulse cyclophosphamide .", "label": "", "metadata": {}, "score": "77.90894"}
{"text": "Panel B. Clusterin expression as revealed by Western blots with anti - CLU antibodies .The results are representative of two biological replicas .Panel C. BS DNA sequencing results of the proximal CLU promoter and part of first exon regions .", "label": "", "metadata": {}, "score": "78.41287"}
{"text": "Patients with versus without prior relapse .Of 1,557 participants eligible for analyses , 310 ( 20 % ) relapsed in the 6 months prior to the study period , and 1,247 ( 80 % ) did not .", "label": "", "metadata": {}, "score": "78.426056"}
{"text": "Nephrology ( Carlton ) 2008 , 13 ( Suppl 2 ) : S24 - 36 .View Article .Jayne D : Challenges in the management of microscopic polyangiitis : past , present and future .", "label": "", "metadata": {}, "score": "78.49954"}
{"text": "View Article .N Engl J Med 2008 , 359 : 2790 - 2803 .View Article PubMed .American College of Rheumatology Annual Meeting .", "label": "", "metadata": {}, "score": "78.61222"}
{"text": "EMBASE ( 1980 to July 2009 ) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs ( [ 28 ] ) together with the a search strategy developed with input from the Cochrane Renal Group 's Trial Search Co - ordinator .", "label": "", "metadata": {}, "score": "78.80982"}
{"text": "Three 1 hour sessions of lymphocytapheresis on alternate days in each of three consecutive weeks .Immunosuppression as for control group .1 G MP iv for 3 consecutive days in each of three consecutive weeks .", "label": "", "metadata": {}, "score": "78.87036"}
{"text": "The Children 's Hospital at Westmead , Sydney , Australia School of Public Health , University of Sydney .References .Savage CO , Harper L , Adu D : Primary systemic vasculitis .", "label": "", "metadata": {}, "score": "78.993324"}
{"text": "Focal necrotizing GN with crescents ( Wegener 's granulomatosis , systemic vasculitis , polyarteritis , idiopathic RPGN ) .Anti - GBM disease , SLE , Henoch - Schonlein Purpura , chronic GN Previously treated with IV MP , oral CPA or PE .", "label": "", "metadata": {}, "score": "78.998505"}
{"text": "Search methods for identification of studies .Relevant studies were obtained form the following sources .The Cochrane Renal Group 's specialised register and the Cochrane Central Register of Controlled Trials ( CENTRAL ) in The Cochrane Library , ( Issue 1 , 2008 ) .", "label": "", "metadata": {}, "score": "79.22468"}
{"text": "ti , ab .cross - over studies/(14545 ) .( crossover or cross - over or cross over ) .tw .( ( singl$ or doubl$ or trebl$ or tripl$ ) adj25 ( blind$ or mask$ ) ) .", "label": "", "metadata": {}, "score": "79.721344"}
{"text": "In this study , we assessed 67LR detection in diagnostic PC biopsies as a predictor of biochemical relapse after RP .METHODS : Diagnostic biopsy and subsequent RP tissue specimens from 151 patients with clinically localized PC were immunohistochemically analyzed for 67LR expression .", "label": "", "metadata": {}, "score": "79.72717"}
{"text": "Evidence increasingly points to the pathogenicity of ANCA [ 4 ] .Other conditions also cause vasculitis in the kidney such as Henoch Schonlein Purpura and cryoglobulinaemia resulting in immune deposits visible on electron microscopic examination of renal tissue .", "label": "", "metadata": {}, "score": "80.77157"}
{"text": "Co- trimoxazole for relapse prevention .Stegeman [ 41 ] studied the efficacy of co - trimoxazole in preventing relapse of patients with ANCA associated vasculitis .", "label": "", "metadata": {}, "score": "81.12523"}
{"text": "On the other hand the surgical procedure is simple and the morbidity is low .The authors report their experience of 148 radical prostatectomies performed for adeno - carcinoma .", "label": "", "metadata": {}, "score": "81.189865"}
{"text": "EMBASE ( 1980 to July 2009 ) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs ( [ 28 ] .", "label": "", "metadata": {}, "score": "81.26718"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .US Outcomes Research , Eli Lilly and Company , Lilly Corporate Center .", "label": "", "metadata": {}, "score": "81.60803"}
{"text": "Methods : Gene promoter methylation is associated with prostate cancer and has been successfully used for the molecular detection of neoplasia in urine .We have developed real - time methylation specific PCR assays to define the methylation status of several genes .", "label": "", "metadata": {}, "score": "81.77821"}
{"text": "Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay , the My Profile \u2122 AML Risk of Relapse Assay .Molecular markers analyzed include Flt3-ITD , NPM1 , and MRA .", "label": "", "metadata": {}, "score": "82.08821"}
{"text": "Complementary investigations useful for the diagnosis of pelvic lipomatosis are CT and especially MRI , intravenous urography and biopsies .The clinical features , radiological findings and therapeutic approach are discussed in the light of a review of the literature .", "label": "", "metadata": {}, "score": "82.154465"}
{"text": "Further studies are required to more clearly delineate the appropriate place of newer agents within an evidence - based therapeutic strategy .Background .Renal vasculitis presents as rapidly progressive glomerulonephritis ( RPGN ) which comprises a group of conditions characterised by acute kidney failure ( AKF ) , haematuria and proteinuria .", "label": "", "metadata": {}, "score": "82.19999"}
{"text": "Relevant studies were obtained form the following sources ( see Appendix 1 for more detail ) : .The Cochrane Renal Group 's specialised register and the Cochrane Central Register of Controlled Trials ( CENTRAL ) in The Cochrane Library , ( Issue 1 , 2008 ) .", "label": "", "metadata": {}, "score": "82.27878"}
{"text": "Mauri 1985 .Histologically proven crescentic GN and rapidly progressive renal impairment .Less than 60 % glomerular involvement , primary glomerulopathies , transplanted kidneys , SLE , HSP .", "label": "", "metadata": {}, "score": "82.68616"}
{"text": "18 or 30 ( 643563 ) .9 and 31 ( 3934 ) .exp wegener 's granulomatosis / or wegener 's granulomatosis.mp . exp Rapidly progressive glomerulonephritis / or rapidly progressive glomerulonephritis.mp . exp neutrophil cytoplasmic antibody / or neutrophil cytoplasmic antibody.mp .", "label": "", "metadata": {}, "score": "83.33099"}
{"text": "Affiliated with .Abstract .Background .Renal vasculitis presents as rapidly progressive glomerulonephritis and comprises of a group of conditions characterised by acute kidney failure , haematuria and proteinuria .", "label": "", "metadata": {}, "score": "83.65432"}
{"text": "- trimoxazole has been used in Wegener 's granulomatosis mainly to prevent the occurrence of pneumocystis infection , upper respiratory tract infection and subsequent relapse of disease .", "label": "", "metadata": {}, "score": "84.63298"}
{"text": "Need a new registration confirmation email ?Click here .Senesco Adds Second Clinical Site To Evaluate SNS01-T In Multiple Myeloma .The University of Arkansas for Medical Sciences ( \" UAMS \" ) is one of the region 's major academic health centers , located in Little Rock , Arkansas , with outreach programs operating in every county and a regional campus in Northwest Arkansas .", "label": "", "metadata": {}, "score": "85.05189"}
{"text": "The authors report two cases of pelvic lipomatosis associated with glandular cystitis .This is a rare disease with variable and nonspecific clinical features .The authors report two cases of pelvic lipomatosis associated with glandular cystitis .", "label": "", "metadata": {}, "score": "86.22089"}
{"text": "Int J Artif Organs 1999 , 22 : 81 - 87 .PubMed .N Engl J Med 2003 , 349 : 36 - 44 .", "label": "", "metadata": {}, "score": "86.48357"}
{"text": "Included and excluded studies .The review was undertaken by three authors ( GW , NW , JC ) .The titles and abstracts were screened independently by GW and NW who independently assessed abstracts .", "label": "", "metadata": {}, "score": "87.002335"}
{"text": "Echographic criteria to define simple versus complicated cysts were detailed .We reviewed the clinical presentation , diagnostic modalities , indications for invasive procedures and postoperative outcome .", "label": "", "metadata": {}, "score": "87.13551"}
{"text": "INTRODUCTION & OBJECTIVES :The identification of reliable prognostic indicators for prostate cancer ( PC ) is a major challenge of today cancer research .INTRODUCTION & OBJECTIVES :", "label": "", "metadata": {}, "score": "87.441574"}
{"text": "Therefore we will not specifically search conference proceedings .Please refer to The Cochrane Renal Group 's Module in The Cochrane Library for the most up - to - date list of conference proceedings ( Renal Group 2008 ) .", "label": "", "metadata": {}, "score": "87.85907"}
{"text": "The online version of this article ( doi : 10 .1186/\u200b1471 - 244X-10 - 2 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "90.600296"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "91.65163"}
{"text": "These procedures included transperineal or transrectal puncture in 9 patients , simple endoscopic section of the utricle meatus in 12 and large marsupialisation in 6 .", "label": "", "metadata": {}, "score": "91.9056"}
{"text": "Our lithotripter is no exception .Extracorporeal shockwave lithotripsy ( ESWL ) has been initially designed for stones located in the kidney and the upper ureter .", "label": "", "metadata": {}, "score": "94.420425"}
{"text": "The 67-KD laminin receptor ( 67LR ) is a cell surface associated molecule whose increased expression is associated with the aggressiveness of a variety of human cancers .", "label": "", "metadata": {}, "score": "94.465195"}
{"text": "Department of Public Policy , University of Maryland , Baltimore County .University of Maryland School of Medicine .VA VISN 5 Mental Illness Research , Education , and Clinical Center , US Department of Veterans Affairs .", "label": "", "metadata": {}, "score": "95.85475"}
{"text": "The 67-kD laminin receptor ( 67LR ) is a cell - surface - associated protein involved in the acquisition of the invasive and metastatic phenotype of a variety of human cancer cell types .", "label": "", "metadata": {}, "score": "96.981735"}
{"text": "exp polyarteritis nodosa / or polyarteritis nodosa.mp .exp acute glomerulonephritis / or acute glomerulonephritis.mp .exp proliferative glomerulonephritis / or proliferative glomerulonephritis.mp .exp glomerular basement membrane antibody / or glomerular basement membrane antibody.mp .", "label": "", "metadata": {}, "score": "97.64945"}
{"text": "View Article PubMed .Pre - publication history .Copyright .\u00a9Ascher - Svanum et al .2010 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "101.61206"}
{"text": "Authors ' Affiliations .Senior Staff Specialist , The Canberra Hospital , Canberra , Australia .Hon .Senior Lecturer , Australian National University Medical School .", "label": "", "metadata": {}, "score": "102.35098"}
{"text": "Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies .Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies .", "label": "", "metadata": {}, "score": "102.87196"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00355134 .Multiple Sclerosis Multiple Sclerosis , Relapsing - Remitting Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases , CNS Demyelinating Diseases Immune System Diseases .", "label": "", "metadata": {}, "score": "105.356316"}
{"text": "View Article PubMed .Pre - publication history .Copyright .\u00a9 Walters et al .2010 .This article is published under license to BioMed Central Ltd. 1 Department of Dermatology , Yale University School of Medicine , New Haven , Connecticut , United States of America . ruth.halaban@yale.edu .", "label": "", "metadata": {}, "score": "109.13745"}
{"text": "PURPOSE : We define guidelines for the exploration and treatment of adult mullerian duct cysts .PURPOSE : We define guidelines for the exploration and treatment of adult mullerian duct cysts .", "label": "", "metadata": {}, "score": "109.35843"}
